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DIETARY INTAKE AND URINARY EXCRETION OF PHYTOESTROGENS IN 
RELATION TO CANCER AND CARDIOVASCULAR DISEASE 
 
Phytoestrogens that abound in soy products, legumes, and chickpeas can induce 
biologic responses in animals and humans due to structural similarity to 17β-estradiol.  
Although experimental studies suggest that phytoestrogen intake may alter the risk of 
cancer and cardiovascular disease, few epidemiologic studies have investigated this 
research question.  This dissertation investigated the associations of intake of total and 
individual phytoestrogens and their urinary biomarkers with these chronic conditions 
using data previously collected from two US national cohort studies (NHANES and 
PLCO).   
Utilizing NHANES data with urinary phytoestrogen concentrations and follow-up 
mortality, Cox proportional hazards regression (HR; 95% CI) were performed to evaluate 
the association between total cancer, cardiovascular disease, and all-cause mortality and 
urinary phytoestrogens.  After adjustment for confounders, it was found that higher 
concentrations of lignans were associated with a reduced risk of death from 
cardiovascular disease (0.48; 0.24-0.97), whereas higher concentrations of isoflavones 
(2.14; 1.03-4.47) and daidzein (2.05; 1.02-4.11) were associated with an increased risk.  
A reduction in all-cause mortality was observed for elevated concentrations of lignans 
(0.65; 0.43-0.96) and enterolactone (0.65; 0.44-0.97).   
Utilizing PLCO data and dietary phytoestrogens, Cox proportional hazards regression 
examined the associations between dietary phytoestrogens and the risk of prostate cancer 
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incidence.  After adjustment for confounders, a positive association was found between 
dietary intake of isoflavones (1.58; 1.11-2.24), genistein (1.42; 1.02-1.98), daidzein 
(1.62; 1.13-2.32), and glycitein (1.53; 1.09-2.15) and the risk of advanced prostate 
cancer.  Conversely, an inverse association existed between dietary intake of genistein 
and the risk of non-advanced prostate cancer (0.88; 0.78-0.99) and total prostate cancer 
(0.90; 0.81-1.00). 
C-reactive protein (CRP) concentration levels rise in response to inflammation and 
higher levels are a risk factor for some cancers and cardiovascular disease reported in 
epidemiologic studies.  Logistic regression performed on NHANES data evaluated the 
association between CRP and urinary phytoestrogen concentrations.  Higher 
concentrations of total and individual phytoestrogens were associated with lower 
concentrations of CRP. 
In summary, dietary intake of some phytoestrogens significantly modulates prostate 
cancer risk and cardiovascular disease mortality.  It is possible that these associations 
may be in part mediated through the influence of phytoestrogen intake on circulating 
levels of C-reactive protein. 
 
 
 
Terrell W. Zollinger, DrPH, Chair 
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Chapter 1 
General Introduction 
Distribution and Burden of Cancer and Cardiovascular Disease 
Cardiovascular disease and cancer are the two leading causes of death in the United 
States (1) and many other developed countries throughout the world (2).  In 2010 in the 
US there were a total of 597,689 deaths due to cardiovascular disease and 574,743 deaths 
due to all types of cancer.  These two types of chronic diseases accounted for 47.5% of 
the total deaths in the US in 2010 (1).  On a global scale, cardiovascular disease is the 
leading cause of death worldwide, estimated to account for 13.2 million deaths in 2011 
(2).  Total cancer claimed an estimated 8.2 million lives worldwide in 2012 (3).  Cancers 
of the lung and bronchus are the most common incident forms of cancer as well as the 
leading cause of cancer death in the US, accounting for an estimated 224,210 new cases 
and 159,260 deaths in 2014 (4).  Prostate cancer is the leading form of incident cancer 
(estimated 233,000 cases in 2014) and second leading cause of death (estimated 29,480 
deaths in 2014) among American men (4).     
The causes of prostate cancer are not yet completely understood, however, past 
studies have established several risk factors that may increase the risk of prostate cancer 
development.  Most of the risk factors that have been established are non-modifiable, 
such as age (prostate cancer risk rises rapidly after the age of 50, and nearly two out of 
three cases are found in men over the age of 65), race/ethnicity (African-Americans are 
more likely to develop and twice as likely to die from prostate cancer), and family history 
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of disease (having a first degree relative with prostate cancer doubles the risk of prostate 
cancer) (4).  Evidence has also suggested that there are several genes that may cause an 
increased risk of prostate cancer and account for between 5% and 10% of the total cases.  
Genetic mutations in the Hereditary Prostate Cancer Gene 1 (HPC1), the androgen 
receptor, and the vitamin D receptor have all been linked to an increased risk of prostate 
cancer (5).  Modifiable risk factors such as obesity (6), smoking (7), consuming higher 
amounts of red meat and lower fruits and vegetables (8), or lower levels of vitamin D (9) 
have also been associated with an increased risk of prostate cancer incidence or mortality. 
Factors that increase the risk of cardiovascular disease, both non-modifiable and 
modifiable, are more established than risk factors for prostate cancer.  Non-modifiable 
risk factors that increase the risk of cardiovascular disease include age (approximately 
82% of cardiovascular disease deaths occur after the age of 65), gender (men are at a 
greater risk than women), and race (African-Americans) (10).  In addition to these non-
modifiable factors, a global case-control study across 52 countries established several 
modifiable risk factors regardless of race and gender.  The modifiable risk factors with 
the greatest increased risk of cardiovascular disease included being a current smoker 
(OR: 2.87; 95% CI: 2.58, 3.19), psychosocial factors (OR: 2.67; 95% CI: 2.21, 3.22), 
history of hypertension (OR: 1.91; 95% CI: 1.74, 2.10) and abdominal obesity (OR: 1.62; 
95% CI: 1.45, 1.80).  This study also identified several factors that decrease the risk of 
cardiovascular disease, including daily consumption of fruits and vegetables (OR: 0.70; 
95% CI: 0.62, 0.79) and regular physical activity (OR: 0.86; 95% CI: 0.76, 0.97) (11). 
Although several risk factors have been established for both prostate cancer and 
cardiovascular disease, it is important to continue to identify modifiable factors that may 
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decrease the burden of these diseases in the US and on a global scale.  One such 
modifiable factor that has thus far not been definitively explored is diet, particularly the 
intake of phytoestrogens and the resulting influence on the incidence and mortality of 
both prostate cancer and cardiovascular disease.  Phytoestrogens are a group of non-
steroidal plant metabolites that are structurally similar to 17β-estradiol and therefore have 
the ability to bind to estrogen receptors (12).  The main forms of phytoestrogens and their 
metabolites are briefly reviewed below. 
Sources and Biochemistry of Estrogen and Phytoestrogens 
Estrogen 
Estrogens are a group of compounds that are named for their importance in both the 
menstrual and estrous reproductive cycles.  Natural estrogens are steroid hormones and 
are the primary female sex hormone (13).  Like other hormones of the steroid class, 
estrogens diffuse across the cell membrane, and upon entering the interior of the cell, 
bind to and activate estrogen receptors.  Activation of estrogen receptors modulates the 
expression of many genes (14). 
The three main forms of naturally occurring estrogens in women are estrone (E1), 
estradiol (E2), and estriol (E3).  Estradiol is the most predominant estrogen during a 
woman’s reproductive years in terms of both the absolute level found in the serum as 
well as in terms of estrogenic activity (15).  Estriol is the most plentiful of the three 
estrogens but also the weakest, with estradiol showing a potency of approximately 80 
times that of estriol (16).  Thus, estradiol is the most important of the naturally occurring 
estrogen hormones in females who are between the stages of menarche and menopause.  
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An exception to this rule occurs during pregnancy when the most important role shifts to 
estriol.  In post-menopausal women, estrone becomes the primary form of estrogen found 
in the body (17). 
Estrogens in non-pregnant females are produced primarily by the ovaries.  Follicle 
stimulating hormone (FSH) stimulates the production of estrogens in the ovaries by the 
granulosa cells of the ovarian follicles and corpora lutea.  Some forms of estrogens are 
produced in smaller amounts by other tissues in the female body including the liver, 
adrenal glands, and the breasts.  Estrogens produced from these secondary sources are 
most important in post-menopausal women (18). 
The actions that result from estrogen are mediated by the estrogen receptor (ER).  The 
estrogen receptor is a dimeric nuclear protein that binds to DNA and controls gene 
expression.  The estrogen-receptor complex can then bind to specific DNA sequences to 
activate the transcription of target genes.  Since estrogen has the ability to enter all cells 
through passive diffusion across the cell membrane, its actions are dependent on the 
presence and availability of the estrogen receptors located within the cells.  The estrogen 
receptors are expressed mainly in the specific tissues of the ovary, uterus, and breast (19). 
In addition to the activation of genes, estrogen serves many additional purposes in the 
human body, mostly in females.  Some of the additional functions include: 
- Structural 
o Promote development of female secondary sex characteristics (20) 
o Accelerate metabolism (21) 
o Stimulate endometrial growth (22) 
o Increase uterine growth (23) 
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o Reduce bone resorption, and therefore increase bone formation (24) 
- Protein synthesis 
o Increase the hepatic production of binding proteins (25) 
- Coagulation 
o Decreases platelet aggregation (26) 
o Decrease antithrombin III (27) 
- Lipid 
o Increase HDL, triglyceride (28) 
o Decrease LDL, fat deposition (21) 
- Fluid balance 
o Sodium and water retention (29) 
- Gastrointestinal tract 
o Reduce bowel motility (30) 
- Uterine lining 
o Together with progesterone, estrogen promotes and maintains the uterine 
lining in preparation for implantation of a fertilized egg (31) 
- Ovulation 
o A surge of estrogen induces the release of luteinizing hormone which 
triggers ovulation (32) 
 
 
 
 
5 
 
Phytoestrogens 
Phytoestrogens are naturally occurring plant compounds that are both structurally and 
functionally similar to the estrogen hormone found in mammals.  Most phytoestrogens 
are phenolic compounds of which isoflavones are the most widely researched 
metabolites.  Isoflavones are found in a wide variety of foods, including berries, wine, 
grains, and nuts but are most abundant in soybeans and therefore a wide variety of soy 
products (33).  The common biological roles of phytoestrogens are to protect plants from 
stress as well as to act as part of the plants defensive mechanisms (34).  Some ecologists 
have speculated that phytoestrogens in plants may have evolved to protect the plants by 
interfering with the reproductive ability of grazing animals (35). 
Phytoestrogens have the ability to cause estrogenic and/or antiestrogenic effects in 
mammals due to their structural similarity to the hormone 17β-estradiol.  In general, 
phytoestrogens are relatively weak estrogens, requiring a much higher concentration than 
their human hormone counterpart in order to produce an equivalent biological response.  
Since isoflavones are found in a wide variety of foods regularly consumed by humans, 
this class has generated the most interest in recent studies (36). 
Phytoestrogens exert their effects primarily through binding to estrogen receptors in 
the human body.  There are two variants of the estrogen receptor (ER), alpha (ER-α) and 
beta (ER-β).  Many phytoestrogens have displayed a higher affinity for the beta estrogen 
receptor compared to the alpha estrogen receptor (37).  There are several key structural 
elements that enable phytoestrogens to bind with a high affinity to estrogen receptors and 
therefore display effects that are similar to the human hormone, these key structural 
elements include: 
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• A phenolic ring that is necessary for binding to an estrogen receptor 
• The ring of isoflavones that mimics a ring of estrogens at the estrogen receptor 
binding site 
• A low molecular weight that is very similar to the human hormone estrogen 
• The distance between two hydroxyl groups at the isoflavones nucleus that is 
similar to that occurring in estradiol 
• Optimal hydroxylation pattern (36) 
The main feature of the chemical structure of phytoestrogens that allows for binding 
to the estrogen receptor is the presence of the phenolic ring.  The presence of this 
structure allows phytoestrogens to act as weak estrogen agonists, partial agonists, or as 
antagonists to endogenous estrogens such as estradiol at the estrogen receptor complex.  
Therefore, mimicking the endogenous estrogen, phytoestrogens may have similar effects 
as estrogen, or block the effects of estrogen (38).  Both circulating and urinary 
biomarkers have been developed to assess phytoestrogen intake.   
Blood tests: Phytoestrogens persist in the plasma for approximately 24 hours after 
ingestion.  The plasma half-life for genistein and daidzein is approximately 8 hours in 
adults with peak measurable concentration occurring 6-8 hours after ingestion.  
Adherence to a high soy containing diet will lead to a high steady state of phytoestrogen 
concentration in the plasma.  Adults consuming approximately 50 mg per day of total 
isoflavones will show similar plasma concentrations to those of Japanese citizens who 
consume a higher volume of soy products in their traditional diet (39). 
Urine tests: Most studies attempting to observe phytoestrogen intake have focused on 
urinary excretion as a more effective method of measurement.  The main reason for the 
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tendency to focus on urinary output of phytoestrogens is because of the high 
concentrations that can be found in the urine after soy intake that allows for a more 
accurate measure of the total intake of phytoestrogens.  Nearly all of isoflavones are 
excreted in both the urine and feces within 24 hours after ingestion (40).  There is a 
considerable variation between individuals in bacterial metabolism of daidzein in the gut 
which leads to markedly different urinary concentrations of phytoestrogens in different 
individuals (41).  In NHANES 2001-2002, the mean urine concentration for daidzein in 
the total population ages 6 and older was 48.6 µg/L with a range from the 50th percentile 
to the 95th percentile of 48.5 to 957.0 µg/L (42). 
 
Isoflavones 
Isoflavones are a group of phytoestrogens most commonly found in foods that are 
consumed by humans.  Isoflavones are found in abundance in soy products, legumes, and 
chick peas (43).  The three most prevalent isoflavones that are present in plant based 
foods are genistein, daidzein, and glycitein (36), however the two most studied are 
genistein and daidzein. 
Isoflavones are a subgroup of flavonoids.  Flavonoids are the most common group of 
polyphenolic (organic chemicals that are characterized by the presence of large multiples 
of phenol structural units [C6H5OH – a hydroxyl group that is found on a benzene ring]) 
compounds that are consumed in the human diet and are found exclusively in plants (44).  
The widespread distribution of flavonoids along with their low toxicity compared to other 
plant compounds means that humans ingest significant quantities in their regular diet.  In 
8 
 
vitro studies have shown that flavonoids may have anti-allergic, anti-inflammatory (45), 
anti-microbial (46, 47), and anti-cancer (48) effects on the human body. 
 
Genistein 
Genistein is a phytoestrogen that belongs to the category of isoflavones.  It binds to 
estrogen receptor and exhibits weak estrogenic and weak anti-estrogenic effects (49). 
Genistein also binds to and inhibits protein-tyrosine kinase, which disrupts signal 
transduction and induces cell differentiation.  It also inhibits topoisomerase-II which 
leads to DNA fragmentation and apoptosis (50). 
Exposure to genistein occurs by food intake, principally through foods made with 
soybeans and soy protein.  Isoflavones, such as genistein, found in soy products are 
contained in two chemical forms, aglycones (the unconjugated form) and glucosides 
(which are bound to a sugar molecule).  The main dietary source of genistein is the 
biologically active glucoside genistin.  Digestion or fermentation of soybeans, soy 
protein, or other soy products results in the release of a sugar molecule from the 
isoflavone glycoside, genistin, which results in the isoflavone aglycone, genistein (40).  
Before genistein can act it first must be released from genistin through the release of 
sugar.  This process normally occurs in the stomach through acid hydrolysis or the 
intestine through the action of bacterial enzymes (40).  There is considerable variation in 
the absorption and metabolism of genistein (49). 
Genistein can affect the process by which signals at the surface of the cells are 
transferred to the interior of the cell.  Genistein also inhibits the activity of several 
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enzymes that are important for controlling cell growth and regulations.  The full effect of 
genistein exposure to the human body is still unknown (51). 
Exposure to genistein can be measured by either a blood or urine test; however levels 
vary greatly due to individual variability of the metabolism of genistein (49).  Despite the 
individual variability that has been found, studies have shown that the mean 
concentration of genistein shown through biological measurements in the blood or the 
urine does not differ greatly between men and women.  A study of 1,414 adults from nine 
countries in Europe found that the mean concentration of genistein that was found in the 
plasma of men in the study was 1.77 mg/L and the mean concentration in the plasma for 
women was 1.70 mg/L (52).  In the 2001-2002 National Health and Nutrition 
Examination Survey (NHANES), males and females also had similar levels of genistein 
measured in their urine output; the mean urinary concentration for males was 32.2 µg/L 
and the mean concentration for females was 33.7 µg/L (42). 
 
Daidzein 
Daidzein belongs to the isoflavone class of phytoestrogens.  It binds to estrogen 
receptors and exhibits weak estrogenic and weak anti-estrogenic effects.  Exposure to 
daidzein occurs by food intake, principally through foods made from soybeans or 
containing soy protein.  Like genistein, daidzein is contained in soy products in two 
chemical forms, aglycones (unconjugated form) and glucosides (which are bound to a 
sugar molecule).  The main dietary source of daidzein is the biologically active glucoside 
daidzin.  Like with genistein, fermentation or digestion of soy products results in the 
release of the sugar molecule from the glucoside, daidzin, which results in the formation 
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of the other form, the aglycone daidzein (40).  This process normally occurs in the 
stomach through acid hydrolysis and in the intestine through the action of the bacterial 
enzymes (40). 
In a small proportion of the population, daidzein can be metabolized by the bacteria 
located in the intestine to produce metabolites that have a stronger estrogenic effect than 
daidzein itself.  These metabolites are equol and O-desmethylangolensin (O-DMA).  
Daidzein has the ability to cross the placenta and has been found in breast milk as well 
(38) 
Exposure to daidzein can be measured by either a blood or urine test; however levels 
of daidzein found in the blood or urine vary widely by person due to the variability of an 
individual’s metabolism (38).  Tests have shown however that the mean concentration of 
daidzein found in either the blood or the urine does not differ significantly between men 
and women.  A study of 1,414 adults from nine countries in Europe found that the mean 
concentration of daidzein in the plasma for men was 0.89 mg/L and the mean 
concentration in the plasma for women was 0.80 mg/L (52).  In the 2001-2002 NHANES, 
males and females also had similar levels of daidzein measured in the urine output; the 
mean urinary concentration for males was 49.8 µg/L and the mean concentration for 
females was 53.6 µg/L (42). 
 
Glycitein 
Glycitein belongs to the isoflavone class of phytoestrogens.  It accounts for only 5% 
to 10% of the total isoflavones that are found in soy food products, but may be as high as 
40% in some soy supplements composed mainly of soy germ.  The estrogenic effect of 
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glycitein is considerably weaker than the effects observed by the other soy isoflavones, 
genistein and daidzein.  Because glycitein has a structure that is similar to both genistein 
and daidzein, it may be important to evaluate the estrogenic activity of this isoflavone as 
well, despite accounting for a relatively low proportion of the total isoflavone content 
found in most foods (53). 
 
Coumestrol, Formononetin, and Biochanin A 
Three phytoestrogens, coumestrol, formononetin, and biochanin A, belonging to the 
class of isoflavones, are found to a lesser degree in soy products, legumes, and chick peas 
(54).  Although there is a decreased concentration of these isoflavones in dietary 
products, they still have biologically significant properties that may protect against 
specific cancers or cardiovascular disease.  Coumestrol has been identified as a novel 
reversible ATP competitive casein kinase 2 (CK2) inhibitor (55).  CK2 is involved in 
various cellular events that include proliferation (56), apoptosis (57), and RNA synthesis 
(58).  Overexpression of this protein kinase is associated with multiple types of cancer in 
humans, including cancer of the colon (59), prostate (60), and breast (61).  Through the 
inhibition of CK2 expression, coumestrol has been shown to inhibit the growth of and 
trigger apoptosis in cancer cells (55).   
Formononetin has been identified to have a possible therapeutic effect on acute 
myocardial infarction.  Zhang et al. conducted an experiment on male Sprague-Dawley 
rats in which myocardial infarction was induced.  The rats were randomized to treatment 
groups of different concentrations of a water-soluble derivative of formononetin or a 
control group.  The rats receiving treatment after myocardial infarction showed a number 
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of significant improvements over the untreated group, including a reduced myocardium 
necrosis score, increased cardiac mitochondrial ATP content, and improved ATP 
synthase activity.  The authors concluded from these findings that this derivative of 
formononetin has a protective potential against myocardial infarction injury (62). 
Biochanin A has been identified as having possible chemopreventive actions against 
specific types of cancer (63).  One of the mechanisms for cancer prevention by Biochanin 
A is through induction of sulfotransferases (64), which are a family of drug metabolizing 
enzymes which are important for detoxification (65) and regulation of biological 
metabolism enzyme genes (66).  Improper regulation of sulfotransferases may lead to 
improper functioning of biological signaling molecules, which may result in cancer or 
other diseases (65).  In an experiment conducted by Chen et al., the authors demonstrated 
that treatment with Biochanin A in rats can induce the expression of sulfotransferases, 
thereby promoting proper signaling and preventing certain chronic conditions (64). 
 
Lignans 
Lignans are another class of phytoestrogens that are found in plants.  Plant lignans 
can be metabolized by the intestinal bacteria to form mammalian lignans, enterodiol and 
enterolactone (67).  Flax seed and sesame seed contain the highest levels of lignans in 
food consumed by humans, however other sources include cereals, soybeans, cruciferous 
vegetables, and some fruits (68).  One study of common plant foods discovered that 
flaxseed flour and its defatted meal produced the highest yield of enterodiol and 
enterolactone, up to 800 times higher than other plants (69).  Considering the food 
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sources for both lignans and isoflavones, lignans are considered to be the principal source 
of dietary phytoestrogens in typical Western diets (70). 
Like isoflavones, lignans are also polyphenols.  Since lignans are metabolized by the 
intestinal bacteria into enterodiol and enterolactone, concentrations of these 
phytoestrogens measured in the serum or urine reflect both the dietary intake and the 
activity level of the intestinal bacteria (71).  Studies have shown that lignans may exhibit 
estrogenic or anti-estrogenic (72), anti-oxidative (73), cardioprotective (74), and anti-
cancer (75) effects on the human body. 
 
Enterodiol and Enterolactone 
Enterodiol and enterolactone are known as enterolignans and are converted from 
plant lignans in food consumed by humans in the upper part of the of the intestine by 
aerobic microflora (76).  There are several steps that occur during the conversion from 
plant lignans to enterolignans, including hydrolysis, dehydroxylation, and demethylation.  
This process converts plant lignans to enterodiol, which can be then oxidized to form 
enterolactone.  The conversion of enterodiol to enterolactone depends on the precursor 
and varies from less than 15% to 100% (77).  Enterodiol and enterolactone can be 
measured in both the plasma and urine of humans (78).  Epidemiologic studies have 
shown that both enterodiol and enterolactone may have preventive effects on such 
diseases such as cardiovascular diseases (79) and specific types of cancer (80, 81). 
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Current Experimental and Epidemiologic Evidence 
Phytoestrogens, Total Cancer, and Prostate Cancer 
Biologic Effects 
The majority of studies on the association between phytoestrogens and prostate 
cancer have consisted of experimental studies examining the biologic effects of the 
different phytoestrogen metabolites.  These types of studies include animal models, in-
vivo studies, and gene-studies. 
 
Animal Models 
Relevant studies on the effects of phytoestrogens on prostate cancer in animal models 
consisted of observing the effects on tumors in mice or rats, both in vitro and in vivo.  
Most studies focused on the effects of genistein while one examined the effects of 
daidzein. 
Three relevant published manuscripts observed the effects of genistein on animal 
models.  The first study, conducted by Miekus and Madeja, investigated the effect of 
genistein on the proliferation and migration of rat prostatic carcinoma, with the 
hypothesis that genistein consumption reduces the incidence of metastases.  Observing 
the cells in vitro, the authors concluded that at physiological relevant concentrations, 
genistein inhibited the motility of prostate cancer cells and therefore showed anti-
metastatic activity, which supported the hypothesis.  The authors’ concluded that 
although it appeared that genistein reduces the incidence of metastases in vitro, the in 
vivo mechanisms may be more complex (82). 
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The second study, conducted by Liss et al., observed the differences in genes that are 
differentially regulated in prostate cancer cells treated with purified genistein or other soy 
protein isolates.  The objective of this study was to discover if genistein was the major 
contributor to the anti-cancer effects of soy products seen in other studies, or if all of the 
metabolites found in soy products made contributions to this effect.  In this in vitro study 
of both rat and human prostate cancer cell lines, there were several observations, 
including: 1) soy was more effective than purified genistein on decreasing cancer cell 
growth in certain prostate cancer cell lines, but the dose-related effect on cell 
proliferation was stronger in purified genistein; 2) there was no difference between soy 
and purified genistein on the influence of the steroid pathway; 3) of the eight genes of 
interest in the apoptosis pathway, there was a single gene that was up-regulated by 
purified genistein but not soy; 4) gene expression in cell cycle pathways showed similar 
results from soy and purified genistein; and 5) of the nine genes of interest in the nuclear 
receptors, there was a single gene that was up-regulated from the treatment with purified 
genistein but not soy.  From these observations the authors concluded that genistein is 
likely the major contributor to the effect of soy on prostate cancer cells, however the 
differences in gene expression suggest that there is some complexity in the different 
compounds found in soy proteins (83). 
The third study on genistein conducted by Nakamura et al. examined the effects of 
genistein treatment on advanced stage prostate cancer tumors in white mice in vivo.  
Observations in this study included an increased rate of lymph node and secondary organ 
metastases in the genistein treated white mice compared to the untreated control group 
and cancerous cells in the treated group showed more proliferating cells and fewer 
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apoptotic cells than the untreated group.  These results that showed genistein treatment 
might increase the risk of prostate cancer could be due to the cancerous cell-line that was 
selected.  Genistein is known to have a high binding affinity to estrogen-receptor β and 
the cell line that was chosen for this experiment had exclusive expression of this type of 
receptor.  These observations generated the hypothesis that the tumor stimulatory effects 
are mediated by estrogen-receptor beta activation.  The authors concluded that careful 
selection needs to be made when enrolling patients for treatment with genistein as certain 
cell lines or patients may have differential estrogen-receptor beta expression (84).  
The final relevant animal model study was conducted by Singh-Gupta et al. and 
observed the effect of daidzein on hormone refractory prostate cancer both in vitro and in 
vivo.  This study was designed after evidence emerged that pure genistein promoted 
increased metastasis to lymph nodes and secondary organs (84).  The authors 
hypothesized that daidzein would negate the effects of genistein-induced metastases.  The 
most relevant observations made in this study included: 1) daidzein protects against 
genistein-induced lymph node metastasis, shown by treating prostate tumors with a 
natural formulation of soy isoflavones compared with pure genistein; and 2) daidzein 
alone is less effective than pure genistein or a natural formulation of soy in killing 
cancerous cells.  These results led to the conclusion that the treatment of prostate cancer 
with pure genistein should not be recommended as it appears that daidzein is important to 
suppress the metastatic effects (85). 
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In-Vitro Studies 
In vitro studies on the effects of phytoestrogens on prostate cancer have been much 
more extensive.  Most of these types of studies were attempting to observe a change in a 
specific mechanism within the cancer cell when exposed to phytoestrogens, while others 
examined the combination of phytoestrogens and other forms of treatment. 
Hsieh and Wu observed, like many others, that Asian men exhibit a lower incidence 
of hormone-refractory prostate cancer (HRPC) compared to American men.  
Furthermore, Asian men who move to the United States and adopt an American lifestyle 
and diet show rates of HRPC that is indistinguishable from Caucasian men.  These 
findings suggest that the diet in Asia contains certain ingredients that are protective 
against prostate cancer.  With this observation, these researchers investigated if a 
combination of epigallocatechin gallate (EGCG), genistein, and quercetin (commonly 
found in the Asian diet) may synergize to control proliferation and gene expression in 
prostate cancer cells.  Using an in vitro model with the addition of these phytochemicals, 
Hsieh and Wu observed a suppressed proliferation of the cancer cells, as well as a 
synergy in the expression of the androgen receptor, tumor suppressor p53, and 
detoxification enzyme reductase type 1 (NQO1).  From these observations the authors 
concluded that there was feasibility for the development of a diet-based approach for 
prostate cancer prevention and treatment (86). 
A study conducted by Oh et al. investigated if a combination of the lowering of 
cholesterol and genistein treatment were related to prostate cancer cell survival.  In this 
study, this combination had several effects on the prostate cancer cells, including: 1) 
decreasing the protein expression of prostate Akt as well as the androgen receptors 
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stimulated by EGF and DHT in concentration dependent manners; and 2) inhibiting the 
phosphorylation cascade of Akt, GSK-3beta, and p70S6K.  Both of these effects will 
ultimately inhibit the viability of prostate cancer cells and finally result in increased 
apoptosis.  These results suggested that prostate cancer cells could be effectively 
inhibited by the combination of lowering cholesterol and the addition of genistein to the 
diet (87).   
A study conducted by Swami et al. observed that soy and the isoflavone genistein 
inhibited the development and progression of prostate cancer through the inhibition of 
prostaglandins, which are known stimulators of prostate cancer growth.  In prostate 
cancer cell cultures, genistein reduced the secretion of prostaglandins as well the 
prostaglandin receptor mRNA, thereby demonstrating two mechanisms for the 
prostaglandin biological effects.  This study also included a small, randomized double-
blind clinical trial where patients were given a placebo or soy isoflavone supplements 
prior to prostatectomy.  In the treatment group, the patients showed a decrease in receptor 
mRNA leading to the conclusion that soy isoflavone supplements may be beneficial to 
prostate cancer chemoprevention and treatment (88). 
A study conducted by Xu et al. investigated the target for genistein in prostate cancer 
cells in six different prostate cancer cell lines.  All six cell lines showed that genistein 
bound to mitogen-activated protein kinase 4 (MEK4) causing an inhibition and a 
subsequent decreased expression of matrix metalloproteinase-2 (MMP-2).  The MMP-2 
level in untreated prostate epithelial cells was statistically significantly higher than the 
treated group by 100%.  These observations increased the knowledge of the genistein 
mechanism in prostate cancer cells by leading to the conclusion that MEK4 was the target 
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for genistein in prostate cancer cells and was associated with decreased levels of MMP-2 
(89). 
A study conducted by Yuan-Jing et al. demonstrated that genistein induces apoptosis 
in prostate cancer cells.  In this study the observation was made that the addition of 
genistein to certain prostate cancer cell lines in vitro demonstrated an increased induction 
of apoptosis in prostate cancer cells.  Additionally, genistein did not increase apoptosis in 
normal cells.  These results were observed both with and without the presence of 
survivin, which inhibits the apoptosis protein in cancer cells allowing them to continue to 
grow and proliferate (90). 
Lee et al. investigated if genistein treatment was involved in the regulation of insulin-
like growth factor (IGF-1).  Elevated levels of IGF-1 are associated with increased risk of 
several different types of cancer (including prostate).  The inhibition of IGF-1 and the 
downstream signaling pathways mediated by the activation of the IGF-1 receptor may be 
involved in inhibiting prostate carcinogenesis.  In this study, genistein treatment 
decreased the number of IGF-1 stimulated cells and therefore caused a significant 
inhibition of cell growth that is stimulated by IGF-1.  It was also observed that in treated 
cells genistein inhibited the phosphorylation of the IGF-1 receptor and the downstream 
targets.  These results showed that genistein treatment effectively inhibited cell growth in 
IGF-1 stimulated prostate cancer cells, another mechanism by which genistein treatment 
may be effective in the treatment of prostate cancer (91). 
A study conducted by Zhang et al. investigated if treatment with genistein had an 
effect on prostate cancer stem cells.  Prostate cancer stem cells are involved in both 
tumorigenesis and progression of prostate cancer.  Conventional cancer treatments often 
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fail to eradicate these types of cells, which can often lead to relapse, therefore targeting of 
prostate cancer stem cells may be an important treatment strategy.  Prostate cancer 
tumorsphere cells possess some of the same qualities as prostate cancer stem cells.  In 
this study, genistein inhibited tumorsphere formation, growth of tumorsphere cells, and 
colony formation of prostate cancer cells.  These observations demonstrated that 
genistein may be a dietary phytochemical with the potential to target prostate cancer stem 
cells and therefore limit recurrence (92). 
A study conducted by Adam et al. investigated if the inclusion of dietary 
phytochemicals in combination with an oncolytic adenoviral mutant that has been 
engineered to selectively target tumors with deregulated cell cycle and apoptosis 
pathways could interact synergistically to produce better results.  This study combined an 
oncolytic adenoviral mutant (AdΔΔ) with genistein and other phytochemicals to observe 
the synergistic effects.  This study observed synergistic and increased cell killing in 
prostate cancer cells when genistein and the oncolytic adenoviral mutant were used in 
combination compared with the phytochemicals alone.  In addition, in vivo studies of this 
combination showed reduced tumor growth without toxicity in normal tissue.  These 
findings suggest that the use of phytoestrogens in combination with other treatment types 
might be a feasible anti-cancer strategy (93). 
 
Gene-Studies 
Other studies have investigated the effects of phytoestrogens (mainly genistein) on 
specific prostate cancer genes.  Evidence from these gene studies show that 
phytoestrogens affect many genes in different ways.   
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A study conducted by Majid et al. examined the effect of genistein on the 
minichromosome maintenance (MCM) gene family.  This type of gene is essential for 
DNA replication and is usually upregulated in various types of cancers, including 
prostate cancer.  In this experiment the researchers observed that treatment of cells with 
genistein as well as trichostatin A (TSA) significantly downregulated the expression of 
MCM genes and decreased the S phase of the cell cycle.  In addition, there was an 
observed downregulation of several genes that govern loading of the MCM complex on 
chromatin.  The researchers concluded that treatment of prostate cancer cells with 
genistein might be advantageous since the MCM genes are an excellent anticancer drug 
target.  In addition, genistein is a natural, non-toxic dietary isoflavone which makes it a 
very good therapeutic agent, whereas TSA shows high toxicity (94). 
 A study conducted by Vardi et al. investigated the effects of soy phytoestrogens on 
the methylation of promoter genes in prostate cancer.  This was accomplished using 
methylation-specific PCR on three different prostate cancer cell lines with the objective 
to determine the effects of two soy isoflavones (genistein and daidzein) compared to a 
known demethylating agent as a control.  There were two main findings from this 
experiment: 1) the promoter regions in the prostate cancer cell lines were all strongly 
methylated in the absence of treatment from the phytoestrogens; and 2) after treatment 
with phytoestrogens, demethylation of the promoter regions for the tumor suppressor 
genes (including GSTP1, RASSF1A, EPH2, and BRCA1) occurred and therefore 
enhanced protein expression was observed.  These observations led to the conclusion that 
modifications to DNA such as the demethylation of the promoter regions in tumor 
suppressor genes may be related to the protective effect of soy on prostate cancer (95).  
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An additional study conducted by Adjakly et al. on the demethylating effects of daidzein 
and genistein produced similar results to the Vardi et al. study.  In this experiment, the 
researchers observed a decrease in methylation percentage in cells treated with genistein 
and daidzein compared with untreated cells and the corresponding increase in the 
expression of proteins.  These effects were seen on BRCA1, GSTP1, and EPHB2 genes 
but not on BRCA2 genes.  These authors concluded as well that soy phytoestrogens have 
a protective effect against prostate cancer, but more studies are needed to understand the 
mechanisms (96). 
A study conducted by Phillip et al. investigated the effects of combining genistein and 
a histone deacetylase inhibitor as treatments against prostate cancer cell survival.  Using a 
whole genome methylation profile, the authors observed the genome wide differences in 
genetic and epigenetic responses to genistein in prostate cancer cells, and determined the 
amount of cell proliferation and cell death using the combination treatment.  At decreased 
concentrations of genistein, there was no significant effect on methylation, however the 
combination of genistein with the histone deacetylase inhibitor showed increased cell 
death and decreased proliferation.  This led to the conclusion that there are a number of 
pathways that are affected by genistein and there is a synergistic effect with the 
combination treatment to induce cell death.  These findings could be an additional 
treatment option for early stage prostate cancer (97). 
Finally, Chiyomaru et al. investigated the effects of genistein on the regulation of 
oncogenic microRNA-151 (miR-151) and its target genes.  Oncogenic miR-151 is 
involved in the progression and metastasis of prostate cancer by targeting genes that have 
been suggested to have a tumor suppressor functionality (CASZ1, IL1RAPL1, SOX17, 
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NSBP1, and ARHGDIA).  Treatment of prostate cancer cell lines with a high expression 
of miR-151 with genistein showed a significant downregulation of the expression of miR-
151 compared with the control and significantly inhibited cell migration and invasion.  
Further tests showed that the expression levels of the five target genes were significantly 
different when treated with genistein.  These observations led to the conclusion that 
genistein mediated suppression of oncogenic miRNAs and that genistein ingestion can be 
an important dietary therapeutic strategy for the treatment of prostate cancer (98). 
 
Clinical Trials 
Evidence from the in vitro studies and animal models demonstrates the efficacy of the 
use of soy products and genistein as a prevention method or treatment option for prostate 
cancer.  In addition to these types of studies, there have been a few relevant clinical trials 
that investigated the use of soy products in prostate cancer patients in a controlled setting. 
A study conducted by Tanaka et al. investigated the association between soy 
isoflavone supplements and serum levels of sex hormones implicated in prostate cancer 
development among healthy men.  For this trial, a total of 28 healthy Japanese volunteers 
between the ages of 30 and 59 were given soy isoflavone supplements (60 mg daily) for 
three months.  Of these 28 men, 18 were equol producers and 10 were equol non-
producers.  Equol is metabolized from the intake of daidzein and exhibits weak 
phytoestrogen activity.  It shows an increased affinity for the estrogen receptor β as well 
as to the sex hormone-binding globulin (SHBG) and may inhibit the growth of prostate 
cancer cells.  It has been observed in previous studies that only some people are able to 
metabolize daidzein into equol and the proportions of equol produced differ greatly 
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among races and age groups.  In this experiment the sex hormone levels of the men in the 
study were measured at baseline and after administration of the soy isoflavone 
supplements.  Additional measurements included the serum and urine concentrations of 
daidzein and genistein, and the levels of equol in the fasting blood samples.  The main 
results of this study showed: 1) no change in the serum levels of estradiol and total 
testosterone after the three month supplementation; 2) the serum levels of SHBG 
significantly increased, and the serum levels of free testosterone and dihydrotestosterone 
(DHT) decreased significantly after the three month supplementation; and 3) among the 
10 equol non-producers, equol became detectable in the serum of two of the healthy 
volunteers after three month supplementation.  These results showed that short-term 
supplementation with soy isoflavone supplements stimulated the production of serum 
equol and decreased the serum DHT in healthy volunteers.  This suggests the possibility 
of converting equol non-producers into producers and that a diet based on soy isoflavones 
may be useful in the prevention of prostate cancer (99). 
A true randomized, placebo-controlled, double-blind clinical trial conducted by 
Lazarevic et al. examined the efficacy and safety of genistein intervention in patients with 
localized prostate cancer prior to a radical prostatectomy.  The trial consisted of 54 study 
subjects that were randomized to the treatment group (23 subjects) or the placebo group 
(24 subjects) for three to six weeks prior to radical prostatectomy.  The treatment group 
was given 30mg of synthetic genistein daily in the form of a capsule that was identical in 
both capsule form and container to the placebo group.  Primary outcomes in this trial 
included PSA levels in the serum and prostatic tissue and the serum testosterone levels.  
Secondary outcomes in this trial consisted of: 1) pathological investigation of the 
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removed prostate to analyze changes in the Gleason score, volume of the prostate, and 
extent of tumor stage compared to preoperative biopsies; 2) safety through the reporting 
of adverse events; 3) compliance to the study design; and 4) total genistein plasma 
concentration.  The main results of this study included: 1) a reduction of PSA levels by 
7.8% in the treatment group and a 4.4% increase in the placebo group (p = 0.051); 2) the 
PSA level in the treatment group was reduced in the tumor tissue; 3) total cholesterol was 
significantly lower in the treatment group; 4) no significant effects were seen on thyroid 
or sex hormones; 5) plasma concentrations of genistein were 100 times higher in the 
treatment group after receiving the treatment (p < 0.001; and 6) there were very few 
adverse events reported and all were mild.  These results led to the conclusion that dietary 
genistein from soy products may reduce serum PSA levels without any effects on 
hormones and normalized PSA expression in the malignant prostate cancer tissue, 
meaning there is a possible therapeutic effect by genistein in early prostate cancer (100). 
 
Epidemiologic Studies 
There have been a small number of epidemiological studies investigating the 
association between phytoestrogen intake and the risk of prostate cancer.  The objective 
of these studies was to evaluate the effects of phytoestrogens on prostate cancer risk, 
through both intake and excretion measurements, on very specific, often small, groups of 
subjects.  None of the epidemiologic studies to this point have evaluated the risk of 
prostate cancer associated with phytoestrogens in a large US population.  In addition, 
there have been no studies conducted in the US using the NHANES or PLCO data, or 
utilizing a cohort study design to examine the relationship.  Results of the epidemiologic 
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studies to this point have yielded mixed results.  Research conducted in this dissertation 
will investigate the association between phytoestrogens and prostate cancer in a much 
larger population in the US, which will add to the generalizability.  Additionally, the 
association with phytoestrogens will be observed separately for advanced and non-
advanced prostate cancer, to determine if the risks are different for developing either of 
these two outcomes. 
The earliest studies of the association between phytoestrogen intake or urinary 
excretion and the resulting risk of prostate cancer showed little to no association.  A study 
conducted by Ganry published in 2006 reviewed previous epidemiologic studies that 
provided data on 1) dietary soy intake or flavonoid intake; 2) urinary excretion of 
isoflavones or lignans; or 3) blood measurements of isoflavones or lignans using soy as a 
marker for isoflavone intake.  This review identified eight studies of interest, four case-
control studies and four prospective studies.  The results of most of these studies showed 
no association between phytoestrogen intake or urinary excretion and the risk of prostate 
cancer.  One case-control and one prospective study did observe a statistically significant 
reduced risk.  Many of these studies exhibited design limitations and flaws including very 
small groups of cases and controls, misclassification of soy intake due to measurement 
errors associated with a dietary instrument, a lack of data on phytoestrogen content in 
food at the time the study was conducted, a lack of information about portion size of soy 
product consumption, limiting the study subjects to the Asian population where soy 
consumption is homogeneously high, and recall bias from the food frequency 
questionnaire.  This study concluded that there appeared to be no association with the 
intake or urinary output of phytoestrogens and the risk of prostate cancer, however with 
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the design limitations and flaws make these results difficult to assess and further study is 
needed (101). 
Recent published studies often observed a protective effect between the intake of 
phytoestrogens and the risk of prostate cancer.  A study conducted by Hedelin et al. 
examined the associations between dietary phytoestrogens and serum enterolactone and 
the risk of prostate cancer in a Swedish population.  In this study, dietary intake of 
phytoestrogens was assessed using a food frequency questionnaire, and the reported 
dietary intake of lignans was validated through the measurement of enterolactone in the 
serum.  The association between phytoestrogens and prostate cancer was determined 
through the reported dietary intake of total and individual phytoestrogens and the serum 
enterolactone concentration.  The study design was a population based case-control study 
in Sweden with 1,499 prostate cancer cases and 1,130 controls (with serum enterolactone 
levels available in a smaller subgroup of 209 cases and 214 controls).  Results from this 
case-control study included: 1) high intake of foods rich in phytoestrogens was associated 
with a significant decrease in the risk of prostate cancer (OR for quartile 4 vs. quartile 1: 
0.74; 95% CI: 0.57, 0.95); 2) no observed association between individual phytoestrogens 
and the risk of prostate cancer; and 3) intermediate levels of enterolactone in the serum 
was associated with a decreased risk of prostate cancer (OR for quartile 2 vs. quartile 1: 
0.28; 95% CI: 0.15, 0.55).  From these observations the authors concluded that intake of 
foods high in phytoestrogens is associated with a decreased risk of prostate cancer, which 
represents an opportunity for prostate cancer primary prevention (102).   
A study conducted by Heald et al. investigated the link between phytoestrogens and 
the risk of prostate cancer in Scottish men.  This study was based on the PCANDIET 
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study, a population-based case-control study of prostate cancer in relation to inherited 
susceptibility and diet from the lowlands and central belt of Scotland.  Study subjects 
included 433 cases and 485 controls aged 50-74 years.  The levels of phytoestrogen 
intake were assessed using a self-reported food frequency questionnaire with food values 
of genistein and daidzein extracted.  In addition, a serum concentration of enterolactone 
was obtained from each subject.  Results from this study included: 1) a significant inverse 
association on prostate cancer risk with increased enterolactone concentrations in the 
serum (OR: 0.40; 95% CI: 0.22, 0.71); 2) significant inverse association on prostate 
cancer risk with the consumption of soy foods (OR: 0.52; 95% CI: 0.30, 0.91); and 3) no 
significant associations observed for dietary intake or serum concentrations of individual 
phytoestrogens.  These results led to the conclusion that the intake of soy foods and 
enterolactone metabolized from dietary lignans protect against prostate cancer in older 
Scottish men (103).       
A study conducted by Jackson et al. examined the association between the urinary 
excretion of phytoestrogens and the risk of prostate cancer in Jamaican men.  This was a 
hospital-based case-control study with 175 newly diagnosed cases of prostate cancer and 
194 controls from urology clinics of two major hospitals in Jamaica.  Men with advanced 
cases of metastatic cancer, previous prostate surgery, recent severe weight loss, currently 
on hormonal treatment, or taking finasteride were excluded from the study.  Urine 
samples from these men were tested for concentrations of genistein, daidzein, equol, and 
enterolactone by time-resolved fluoroimmunoassay.  These men were divided into two 
groups of equol producers and non-producers (similar to other studies), with producers 
defined as men with detectable urinary concentrations of equol.  The results from this 
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study included: 1) no significant differences in median concentrations of isoflavones 
from phytoestrogens; 2) compared to non-producers of equol, men who produced equol 
were at decreased risk of total prostate cancer (OR for tertile 2 vs. tertile 1: 0.42; 95% CI: 
0.23, 0.75; OR for tertile 3 vs. tertile 1: 0.48; 95% CI: 0.26, 0.87); 3) compared to non-
producers of equol, men who produced equol were at decreased risk of advanced prostate 
cancer (OR for tertile 2 vs. tertile 1: 0.31; 95% CI: 0.15, 0.61; OR for tertile 3 vs. tertile 
1: 0.29; 95% CI: 0.13, 0.60); 4) higher concentrations of enterolactone were positively 
associated with an increased risk of total prostate cancer (OR: 1.85; 95% CI: 1.01, 3.44); 
5) higher concentrations of enterolactone were positively associated with increased risk 
of advanced prostate cancer (OR: 2.46; 95% CI: 1.11, 5.46); and 6) there were no 
associations between urinary excretion of genistein and daidzein and the risk of prostate 
cancer.  These results led to the conclusion that equol producers may be at reduced risk of 
total and advanced prostate cancer, however enterolactone may increase the risk of total 
and advanced prostate cancer (104). 
A study conducted by Park et al. examined the association between urinary 
phytoestrogen excretion and prostate cancer risk in a group of men aged 45 – 75 years.  
The study design was a nested case-control within a large multiethnic cohort in Hawaii 
and California.  The Multiethnic Cohort Study was established in Hawaii and the Los 
Angeles area of California from 1993-1996 and contained over 215,000 adults who 
completed a detailed questionnaire on diet and lifestyle factors and came from five 
ethic/racial groups: African American, Native Hawaiian, Japanese American, Latino, and 
White.  A smaller subcohort from the larger cohort study had biological specimens of 
blood and/or urine collected, largely between 2001 and 2006.  A total of 249 cases and 
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404 matched controls were determined to be eligible for the nested case-control study.  
Levels of daidzein, genistein, equol, and enterolactone were analyzed in the urine by 
HPLC to determine concentrations.  Results from this study included: 1) an inverse 
association with total prostate cancer risk observed for daidzein (OR for quintile 5 vs. 
quintile 1: 0.55; 95% CI: 0.31, 0.98) across all ethnic groups; and 2) no significant 
association was detected for the risk of total prostate cancer and excretion of genistein, 
equol, or enterolactone.  These results led to the conclusion that high intake of 
isoflavones reflected by the excretion in the urine of daidzein may be responsible for a 
protective effect against prostate cancer (105). 
There were two separate studies conducted by Travis et al. based on the European 
Prospective Investigation into Cancer and Nutrition Cohort (EPIC).  The first study, 
published in 2009, examined the association of plasma concentrations of phytoestrogens 
in relation to the risk of prostate cancer using a nested-case control design of the EPIC 
cohort study.  This study identified 950 prostate cancer cases and 1,042 matched controls 
from the eight participating countries, Denmark, Germany, Greece, Italy, the 
Netherlands, Spain, Sweden, and the United Kingdom.  Cases were defined as men who 
developed prostate cancer after the period of blood collection in the study but before the 
end of the study period.  Exclusions included cases with no blood collection information 
or those who had a history of another type of cancer other than melanoma.  A smaller 
number of participants (675) had information available on tumor stage, of which 475 
were classified as localized prostate cancer and 200 were classified as advanced stage 
prostate cancer.  Matching criteria for the controls included recruitment center, age at 
enrollment within six months, time of day of blood collection within one hour, follow-up 
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time, and time between blood draw and the last consumption of food or drink.  Plasma 
samples for cases and controls were analyzed for three isoflavones (genistein, daidzein, 
and equol) and two lignans (enterolactone and enterodiol).  Relative risks for prostate 
cancer in relation to plasma concentrations of the three phytoestrogens were estimated by 
conditional logistic regression.  The results of this study included: 1) higher 
concentrations of genistein were associated with a lower risk of prostate cancer (RR for 
quintile 5 vs. quintile 1: 0.74; 95% CI: 0.53, 0.96) and after adjustment for potential 
confounders the results were borderline significant (RR for quintile 5 vs. quintile 1: 0.74; 
95% CI: 0.54, 1.00); and 2) there were no statistically significant associations for the risk 
of prostate cancer observed for circulating concentrations of daidzein, equol, 
enterolactone, or enterodiol.  These results led to the conclusion that higher 
concentrations of circulating genistein may reduce the overall risk of prostate cancer, but 
the evidence from this study does not support an association between plasma lignans and 
prostate cancer (106).  The second study conducted by Travis et al. was published in 
2012 as an extension of the first study.  This study added an additional 655 cases and 655 
matched controls using their original inclusion and exclusion criteria for a total of 1,605 
cases and 1,697 matched controls.  The results from this larger follow-up study 
contradicted the results from the first study, showing no observed association between 
genistein concentration and a decreased risk of prostate cancer.  The contradictory nature 
of these findings may be explained from only measuring the serum concentrations of 
circulating genistein once instead of multiple times to obtain an average.  In a population 
with a relatively low intake of isoflavones, one measurement may not be a reliable 
indicator of long-term exposure to genistein and other isoflavones associated with soy 
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products.  The authors also stated that measurement error may be masking an association 
that exists between genistein and prostate cancer risk (107). 
A study conducted by Ward et al. was based on the European Prospective into Cancer 
and Nutrition (EPIC) Norfolk data, with subjects ranging from between the ages of 45-
75.  One objective of this study was to investigate the association between phytoestrogen 
concentrations measured in the serum and urine and the risk of prostate cancer.  From the 
larger cohort study, the authors used a nested case-control design, and identified 193 
incident cases of prostate cancer with 828 controls.  The prostate cancer cases were 
identified a minimum of 12 months after enrollment into the EPIC-Norfolk study.  Data 
collected in this study included health and lifestyle variables, a 7-day food diary, 
anthropometric measurements, and laboratory measures that included concentrations of 
phytoestrogens.  In this study the results of a logistic regression analysis, after the 
adjustment for age, height, weight, and intake of energy, fat, and lycopene, included: 1) 
no significant association between prostate cancer risk and total urinary isoflavones (OR: 
1.01; 95% CI: 0.93, 1.10) or total urinary lignans (OR: 0.94; 95% CI: 0.86, 1.04); and 2) 
similar null associations observed for all urinary and serum levels of individual 
phytoestrogen biomarkers.  These results led to the conclusion that there was no evidence 
to support an association between phytoestrogen exposure and a reduced risk of prostate 
cancer (108).     
Another study by Ward et al., published in 2010, used updated data from the same 
database and phytoestrogen intake from a 7-day dietary instead of serum and urinary 
concentrations of individual phytoestrogens used in the previous study.  This study 
identified 204 cases of prostate cancer and 812 controls.  The results of the multivariate 
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analysis (controlling for age, height, weight, physical activity, social class, family history 
of prostate cancer, and daily intake of energy, fat, zinc, selenium, and lycopene) included: 
1) no observed association between the intake of total phytoestrogens and the risk of 
prostate cancer (OR: 0.86, 95% CI: 0.66, 1.13); and 2) there was a positive association 
approaching significance between the intake of equol and the risk of prostate cancer (OR: 
1.31, 95% CI: 1.00-1.71).  From these results the authors concluded that there was no 
association between the intake of phytoestrogens and the risk of prostate cancer, but 
equol may influence the risk of prostate cancer (109). 
 
Phytoestrogens and Cardiovascular Disease 
Biologic Effects 
Studies on the biological effects of phytoestrogens and cardiovascular disease, 
specifically animal models, in-vivo/in-vitro studies, and gene studies are scarce.   
 
Animal Models 
Only one experimental study based on an animal model was relevant to this research.  
That study, conducted by Kelly et al., investigated the effects of genistein on gene 
expression related to cardiovascular disease in rats that were induced to menopause.  In 
this study, fifty-nine Sprague-Dawley rats had both ovaries removed to induce 
menopause.  After this procedure, they were randomized into four treatment groups and 
one control group.  The control group was fed soy-free food, two of the treatment groups 
were fed soy-free food supplemented with two concentrations of estradiol (0.19 mg and 
0.75 mg), and two treatment groups were fed soy-free food supplemented with two 
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concentrations of genistein (6 mg and 60 mg).  After three months, levels of prothrombin, 
coagulation factor VII, fibrinogen alpha, fibrinogen beta, and C-reactive protein (CRP) 
(all of which have been linked to cardiovascular disease) were tested in all groups.  The 
researchers discovered that gene expression of prothrombin, factor VII, fibrinogen alpha, 
and fibrinogen beta were significantly increased in all of the treatment groups compared 
to the control group.  Additionally, the genistein treatment group also increased factor 
VII significantly more than the estradiol treatment group.  Finally, CRP levels were also 
statistically significantly increased in the treatment groups compared with the control 
group.  Although relating animal models to humans is sometimes difficult, these results 
suggested that genistein may have an adverse effect on cardiovascular health (110).  
 
In-Vitro Studies 
Similar to the experimental study conducted on an animal model, only one in-vitro 
study showed any relevance to the current research.  That study, conducted by Kayisli et 
al., hypothesized that the isoflavone genistein may be involved in the prevention of 
coronary heart disease through the mechanism of regulating the survival of human 
coronary artery endothelial cells (HCAEC).  In order to investigate this hypothesis, the 
researchers performed immunocytochemistry, cell proliferation assay, and apoptosis 
assay on HCAEC’s that were treated with genistein.  HCAEC’s were obtained from three 
healthy postmenopausal women with no known history of cardiovascular disease and 
treated with various concentrations of genistein (111).  Postmenopausal women were 
chosen for this study because of the increase in coronary heart disease that has been 
attributed to the loss cardioprotection due to estrogen deficiency (112).  Control 
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HCAEC’s were treated with the same medium in the absence of genistein.  The main 
findings of this study included a higher affinity for the estrogen receptor β in the 
genistein treated HCAEC’s, decreased HCAEC proliferation in the genistein treatment 
group in a concentration dependent manner compared to the control cells, and an increase 
in the number of apoptotic HCAEC’s in a time-dependent manner.  The results led to the 
conclusion that genistein may not only inhibit the growth of human coronary artery 
endothelial cells, but also may stimulate death of the HCAEC’s as well.  These findings 
appear to cause a prevention of angiogenesis and therefore contradict findings from 
observational studies of the cardioprotective effect of genistein in postmenopausal 
women (111). 
 
Clinical Trials 
The majority of published dietary intervention trials that were conducted on the 
association between phytoestrogens and cardiovascular disease involved small 
populations, mainly consisting of postmenopausal women. 
Two studies observed the association between the phytoestrogen genistein and 
cardiovascular disease on postmenopausal women.  The first study, conducted by 
Crisafulli et al., observed the effect of genistein on specific cardiovascular disease risk 
markers.  In this study, 60 healthy postmenopausal women between the ages of 52 and 60 
were enrolled in a double-blind, placebo controlled, randomized study for six months.  
The treatment group received 54 mg of genistein per day, and the control group received 
a placebo.  Cardiovascular risk markers were measured at baseline and after six months, 
and included glucose, insulin, insulin resistance, osteoprotegrin, fibrinogen, and sex-
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hormone-binding globulin (SHBG).  The genistein treatment group showed a statistically 
significant decrease in fasting glucose, fasting insulin, and insulin resistance compared to 
the placebo group.  These results led to the conclusion that genistein treatment may have 
a beneficial effect on some cardiovascular risk markers, and therefore may potentially 
reduce cardiovascular disease (113).  The second study, conducted by Villa et al., also 
observed the effect of genistein on cardiovascular disease risk markers.  In this study, 50 
postmenopausal women were enrolled in a randomized, placebo controlled study for 24 
weeks.  The treatment group received the same daily dose of genistein (54 mg) while the 
control group received a placebo.  The treatment group was further divided into two 
categories, normoinsulinemic and hyperinsulinemic.  Outcome measures for this study 
included hormonal and lipid assays, oral glucose tolerance test with glycemic, insulin, 
and C-peptide evaluation, and indexes of insulin sensitivity and endothelial function.  The 
genistein treatment group showed significant improvement in insulin sensitivity and 
fasting glucose compared to the placebo group.  In the hyperinsulinemic group, the 
authors observed a significant reduction in fasting insulin and that HDL cholesterol levels 
were significantly improved.  These results led to the conclusion that treatment with 
genistein significantly influenced some of the risk markers of cardiovascular disease in 
both normoinsulinemic and hyperinsulinemic patients (114). 
There are two published studies by Hall et al. on the association between soy 
isoflavone enriched foods and biomarkers of cardiovascular disease risk in 
postmenopausal women.  The first of these studies examined the association between soy 
isoflavones and inflammatory biomarkers (115) and the second examined the association 
between soy isoflavones and markers of lipid and glucose metabolism (116).  Both of 
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these studies used the same group of 117 postmenopausal women, with the study 
designed as a double-blind, placebo-controlled crossover dietary intervention trial.  
Women in the intervention group received an isoflavone-enriched cereal bar with 50 mg 
of total isoflavones (genistein and daidzein) for eight weeks, with an eight-week washout 
period between the crossover.  In the study of isoflavones and inflammatory biomarkers, 
outcomes of interest included von Willebrand factor, intracellular adhesion molecule 1, 
vascular cell adhesion molecule 1, E-selectin, monocyte chemoattractant protein 1, C-
reactive protein (CRP), and endothelin 1 concentrations.  Differences with respect to 
several single-nucleotide polymorphisms were also investigated.  In this study the authors 
observed an improvement in the intervention group for CRP concentrations, but no other 
statistically significant changes were observed for the other outcomes of interest.  This 
led to the conclusion that isoflavones have beneficial effects on CRP concentrations in 
postmenopausal women, but not on other known inflammatory biomarkers (115).  In the 
study of isoflavones and markers for lipid and glucose metabolism, outcomes of interest 
included total, HDL, and LDL cholesterol, triacylglycerols, lipoprotein A, glucose, 
nonesterified fatty acids, insulin, and the homeostasis model assessment of insulin 
resistance.  Differences with respect to single-nucleotide polymorphisms were also 
investigated.  In this study the authors observed no significant beneficial effect on plasma 
concentrations of lipids, glucose, or insulin in the treatment group.  They did however 
observe an increase in HDL cholesterol in the treatment group for one particular 
genotype of an estrogen receptor β gene.  This led to the conclusion that isoflavone 
supplementation does not affect lipid or other metabolic markers of cardiovascular 
38 
 
disease in postmenopausal women, but women with a particular genotype in an estrogen 
receptor gene may see an increase in HDL cholesterol (116). 
The final dietary intervention trial conducted on postmenopausal women also 
included healthy men of a similar age.  In this study, conducted by Teede et al., the 
objective was to observe the cardiovascular effects of dietary phytoestrogens delivered in 
soy products.  A group of 108 men and 105 postmenopausal women between the ages of 
50-75 participated in this 3-month, double-blind, placebo controlled, randomized dietary 
intervention trial.  Individuals in the intervention group received a soy protein isolate 
with 40 g of soy protein and 118 mg of isoflavones, while individuals in the control 
group received a placebo.  Outcomes of interest in this study included blood pressure, 
lipids, vascular function, and endothelial function.  In the intervention group, the authors 
observed a significant decrease in blood pressure, a reduction in the LDL to HDL ratio, a 
reduction in triglycerides, and an overall improved arterial function.  Adverse effects 
observed included a decline in endothelial function in males and an increase in 
lipoprotein A.  This combination of observed results led to the conclusion that further 
research is need in the subpopulations of hypertensive and hyperlipidemic individuals, in 
order to discover a more definitive association (117).    
Another randomized, double-blind, placebo controlled trial was conducted by Qin et 
al. on hypercholesterolemic adults aged 40-65 years.  In this study, the objective was to 
evaluate the effects of the isoflavone daidzein on cardiovascular disease risk factors in 
adults with high cholesterol.  The 177 participants that completed this study were 
randomized to one of three groups, the placebo (control) group, and two intervention 
groups, the first receiving 40 mg of daidzein daily, and the second receiving 80 mg of 
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daidzein daily, for six months.  Outcomes of interest for this study included fasting lipid 
profiles, glucose, serum uric acid concentrations, serum lipoprotein A concentrations, 
blood glycated hemoglobin, and serum insulin.  The results of this study included a 
significant decrease in both treatment groups of serum triglycerides and serum uric acid 
compared to the placebo group, but no additional significant differences were observed 
for any of the other outcomes of interest.  Greater decreases in serum triglycerides were 
observed for the GA genotype of the estrogen receptor β gene RsaI.  These results led to 
the conclusion that daidzein consumption may improve certain cardiovascular risk 
factors, especially in adults with the GA genotype of the estrogen receptor β gene RsaI 
(118). 
Finally, a study was conducted by Wiseman et al. examining the association between 
soy protein containing isoflavones and biomarkers of lipid peroxidation and resistance of 
LDL oxidation.  The design of this study was a randomized, controlled, crossover design 
of 24 adults between the ages of 19 and 40 years of age.  Subjects in this study were 
given either a soy protein supplement that was high in isoflavones or a soy protein 
supplement in which most of the isoflavones had been removed through alcohol 
extraction.  Each of the treatment periods lasted for 17 days, with a 25-day washout 
period between the crossover.  Outcomes of interest for this study included plasma 
concentrations of F2-isoprostane and 8-epi-prostagalndin F2α (biomarkers of lipid 
peroxidation), and the resistance of LDL to copper induced oxidation.  Results from this 
study included a significant reduction in the plasma concentrations of 8-epi-prostagalndin 
F2α and an increased lag time for copper-ion induced LDL oxidation in the high 
isoflavone treatment group.  These results led to the conclusion that the consumption of 
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naturally occurring isoflavones showed an antioxidant effect that may signal a significant 
reduction in the risk of atherosclerosis, cardiovascular disease, and cancer (119).  
 
Epidemiologic Studies 
Similar to the clinical/intervention trials concerning the association between 
phytoestrogens and cardiovascular disease, many of the epidemiologic studies published 
on this topic have focused on postmenopausal women.  Research conducted in this 
dissertation for the association between phytoestrogens and cardiovascular disease will 
utilize a larger population of US adults, aged 18 years and older, which will not only 
investigate the association in a larger group, but should also increase the generalizability 
of the results. 
A study conducted by de Kleijn et al. utilized data from the Framingham study with 
the objective to investigate the association between intake of dietary phytoestrogens and 
metabolic cardiovascular disease risk factors among postmenopausal women.  This cross-
sectional study consisted of data on 939 postmenopausal women taken from the 
Framingham cohort.  Dietary phytoestrogen levels were determined by a food-frequency 
questionnaire.  Cardiovascular disease risk factors of interest included blood pressure, 
waist to hip ratio, and plasma lipoprotein levels.  Analyses were adjusted for age, BMI, 
hormone replacement therapy use, smoking status, fiber intake, and dietary potassium 
intake.  The main results of this study when comparing the highest quartile of 
phytoestrogen intake to the lowest include a decreased waist to hip ratio among women 
for lignan intake, lower triglyceride levels for isoflavones intake, and a lower 
cardiovascular risk factor metabolic score for isoflavone intake.  These results led to the 
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conclusion that high intake of phytoestrogens in postmenopausal women favorably 
altered the cardiovascular risk profile (120). 
A large, prospective cohort study was conducted by van der Schouw et al. on Dutch 
women ages 49-70 years.  The objective of this study was to determine if habitual low 
intake of dietary phytoestrogens was associated with an increase in cardiovascular 
disease risk.  Data on 16,165 women was obtained from the Dutch Prospect-EPIC cohort, 
with the subjects enrolled for a median of 75 months of follow-up.  Phytoestrogen levels 
were estimated through the use of a dietary intake questionnaire.  Cox proportional 
hazards regression was used to estimate the hazard ratios of cardiovascular disease for 
quartiles of dietary phytoestrogen intake.  Variables that were controlled in the model 
included age, BMI, smoking status, physical activity, hypertension, 
hypercholesterolemia, hormone replacement therapy use, menopausal status, and dietary 
intake of total energy, fiber, fruits and vegetables, and alcohol.  The overall results of this 
study showed no significant association between isoflavones or lignans with 
cardiovascular disease risk; however, a significant decreased risk of a cardiovascular 
event was observed for increased lignan intake among smokers.  These results led to the 
conclusion that there is no protective effect associated with a higher intake of 
phytoestrogens associated with cardiovascular disease (121).  
Finally, a study conducted by Pellegrini et al. examined the association between plant 
lignans and both vascular inflammation and endothelial dysfunction among a group that 
consisted of postmenopausal women and men of a similar age in Northern Italy.  This 
was a cross-sectional study design consisting of 242 total subjects (151 males and 91 
females).  The subjects were chosen from a population of workers at a food company in 
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Italy who had originally completed a survey on risk factors for type II diabetes and 
cardiovascular disease.  Subjects enrolled in this study completed a medical history 
questionnaire, a three-day food record, and several lab tests to measure the cardiovascular 
disease outcomes of interest.  These outcomes included serum insulin levels, C-reactive 
protein levels, soluble intercellular adhesion molecule-1, fasting plasma glucose, total 
cholesterol, HDL cholesterol, triacylglycerol, and brachial flow-mediated dilation.  The 
main results of this study included a significant decreased concentration of soluble 
intercellular adhesion molecule-1 and a significant increase in brachial flow mediated 
dilation associated with an increased intake of lignans.  These results led to the 
conclusion that the intake of dietary lignans is associated with a decrease in vascular 
inflammation and endothelial dysfunction among older adults in Northern Italy (122).  
There have been very few epidemiologic studies that have focused on a healthy adult 
population instead of specific populations such as postmenopausal women.  One such 
study, conducted by Guo et al., examined the relationship between the daidzein 
metabolites, equol and O-desmethylangolensin and the association with serum lipids and 
uric acid in an adult population in China.  A total of 210 subjects between the ages of 20 
and 69 were recruited into this cross-sectional study.  Data were collected on fasting 
serum lipids, glucose, and uric acid, along with both dietary intake and urinary 
concentrations of phytoestrogens.  The main results of this study included a significantly 
decreased serum uric acid and waist to hip ratio among subjects who produced equol.  No 
significant differences were observed in serum lipids, glucose, and uric acid among 
subjects who produced O-desmethylangolensin.  This led to the conclusion that 
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individuals who produce equol may show a decreased risk of cardiovascular disease 
compared to those who are non-producers (123). 
Rationale for Research Reported in this Dissertation 
Biological evidence exists in the form of both animal models and in vitro studies that 
suggests that an increased intake of phytoestrogens should produce a protective effect 
against prostate cancer, however, evidence suggesting a protective association between 
phytoestrogens and cardiovascular disease has thus far not been adequately researched.  
Small clinical trials have observed that an increase in phytoestrogen intake may have 
therapeutic effects towards the prevention and treatment of both prostate cancer and 
cardiovascular disease.  Epidemiologic studies to this point have produced mixed results 
with some studies showing an inverse relationship between phytoestrogens and prostate 
cancer or cardiovascular disease risk and others showing no association.  Most published 
epidemiologic studies have focused only on the association in a specific group.  In 
addition, there have been very few epidemiologic studies conducted on the relationship 
between phytoestrogen intake and the risk of prostate cancer in the United States and 
even fewer examined the differences in the relationship between phytoestrogen intake 
and the risk of total versus advanced prostate cancer.  To this point there have been no 
epidemiologic studies on this topic published utilizing the data from the National Health 
and Nutrition Examination Survey (NHANES) or the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO).  Both of these studies contain a great deal of 
data with the potential to produce results on the relationship between phytoestrogens and 
prostate cancer or cardiovascular disease among a large population in the US.  
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Outline of the Dissertation 
The research for this dissertation utilized the NHANES and PLCO data to investigate 
the relationship between phytoestrogen intake and the risk of prostate cancer or 
cardiovascular disease.  Although there are several types of hormone related cancers that 
could be influenced by the dietary intake of phytoestrogens, this research chose to focus 
on prostate cancer for several reasons: 1) prostate cancer affects a large population of 
men in the US (4); 2) most of the established risk factors for prostate cancer are non-
modifiable (4, 5), and many modifiable factors have not been adequately explored; and 3) 
biological evidence suggests that advanced and non-advanced cases of prostate cancer 
may not be etiologically similar (124), which means that the risk factors may be different 
as well.  In the first study using the NHANES data, the investigation focused on the 
relationship between urinary excretion of total and individual phytoestrogens and the risk 
of total cancer, cardiovascular disease, and all-cause mortality.  Previous epidemiologic 
studies focused on the incidence of these diseases and not the mortality.  This will be the 
first time that the NHANES data has been used for this type of study.  In the second 
study, using data from the PLCO, the investigation focused on the relationship between 
the dietary intake of total and individual phytoestrogens and the risk of the development 
of total, advanced, and non-advanced prostate cancer. The division of prostate cancer into 
both advanced and non-advanced cases in the US and the association with phytoestrogens 
has thus far not been studied.  In the third study using NHANES data, the investigation 
focused on the relationship between urinary excretion of total and individual 
phytoestrogens and the levels of C-reactive protein (CRP).  CRP is a common biomarker 
for inflammation that has been associated with an increased risk of both cardiovascular 
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disease and certain types of cancer.  The results of these studies using the large NHANES 
and PLCO datasets should add valuable knowledge on the relationship between 
phytoestrogens and these chronic conditions. 
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Chapter 2 
Urinary Phytoestrogens and Cancer, Cardiovascular, and All-Cause Mortality in 
the Continuous National Health and Nutrition Examination Survey 
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Abstract 
Scope: Experimental studies suggest that phytoestrogen intake alters cancer and 
cardiovascular risk.  This study investigated the associations of urinary phytoestrogens 
with total cancer (n=79), cardiovascular (n=108), and all-cause (n=290) mortality among 
5,179 participants in the continuous National Health and Nutrition Examination Survey 
(1999-2004).  
Methods and Results: Survival analysis was performed to evaluate hazard ratios (HRs) 
and 95% confidence intervals (CIs) for each of the three outcomes in relation to urinary 
phytoestrogens.  After adjustment for confounders, higher urinary concentrations of total 
lignans were associated with a reduced risk of death from cardiovascular disease (HR for 
tertile 3 vs. tertile 1: 0.48; 95% CI: 0.24, 0.97), whereas higher urinary concentrations of 
total isoflavones (HR for tertile 3 vs. tertile 1: 2.14; 95% CI: 1.03, 4.47) and daidzein 
(HR for tertile 3 vs. tertile 1: 2.05; 95% CI: 1.02, 4.11) were associated with an increased 
risk.  A reduction in all-cause mortality was observed for elevated urinary concentrations 
of total lignans (HR for tertile 3 vs. tertile 1: 0.65; 95% CI: 0.43, 0.96) and enterolactone 
(HR for tertile 3 vs. tertile 1: 0.65; 95% CI: 0.44, 0.97). 
Conclusion: Some urinary phytoestrogens influenced cardiovascular and all-cause 
mortality in a representative sample of the US population.  
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Introduction 
Cardiovascular disease and cancer are the leading causes of death in the United States 
(1) and many other developed countries throughout the world (2).  In the United States, 
597,689 cardiovascular deaths and 574,743 cancer deaths occurred in 2010 (1).  On a 
global scale, cardiovascular disease was estimated to account for over 13.2 million deaths 
in 2011 (2), and total cancers claimed an estimated 8.2 million lives in 2012 (3).  To 
prevent the development of cancer and cardiovascular disease, it is necessary to identify 
their risk factors, particularly modifiable ones.  One such modifiable factor is diet.  
Phytoestrogens are a group of non-steroidal plant metabolites.  The principal classes 
of phytoestrogens include isoflavones and lignans.  Isoflavones abound in soy products, 
legumes, and chick peas (43, 125), and lignans primarily originate from seed oils, whole 
grain cereals, and beans (126).  Isoflavones found in soy products include genistein, 
daidzein, and glycitein (127), with these compounds arising after metabolism by the gut 
bacteria of the glycoside conjugates (128).  Daidzein can be further converted into two 
endogenous metabolites, equol and O-desmethylangolensin, with individual variation in 
the metabolism of daidzein in populations (129, 130).  Plant lignans commonly consumed 
by humans are converted into mammalian lignans, enterolactone and enterodiol, by the 
intestinal bacteria (131).  Differences in the biochemistry and food sources of individual 
phytoestrogen compounds requires investigation of total phytoestrogens and their 
metabolites in relation to disease risk. 
 A growing body of experimental evidence suggests that it is biologically plausible 
that phytoestrogen intake may modulate the risk of cancer and cardiovascular disease 
(132, 133).  Phytoestrogens can induce biologic responses due to their structural 
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similarity to 17β-estradiol when they are consumed in the diet (12).  The biologic 
responses from phytoestrogens include estrogenic, anti-estrogenic, anti-oxidative, anti-
viral, anti-bacterial, and anti-proliferative effects (131).  It has been found that the 
potential beneficial effect of phytoestrogens on some hormone-related cancers (134, 135) 
is mediated through their competitive binding to estrogen receptors (136, 137).  While 
estradiol exhibits an equal affinity to both α and β receptors (ERα and ERβ), 
phytoestrogens show a stronger affinity to ERβ (138).  For example, genistein has an 
approximately 30-fold greater affinity to the ERβ, and therefore may cause some clinical 
effects by selectively triggering this particular receptor (138).  Administration of 
phytoestrogens reduced serum testosterone levels in rats, an established risk factor for 
prostate cancer (132, 139).  It was also found that soy phytoestrogens reversed severe 
pulmonary hypertension and prevented heart failure in the same animals (133).   
Despite experimental evidence, few epidemiologic studies have examined the 
association between phytoestrogen intake and cancer or cardiovascular mortality in 
Western populations.  Previous studies have focused on a few sites of cancer, mainly 
prostate (140, 141) and breast (142, 143), yielding mixed results.  Little is known about 
the association between phytoestrogen intake and cardiovascular disease (144), although 
it is considered a promising area of research for cardiovascular disease prevention (145).  
The consumption of soy products is lower in Western countries than in Asian countries 
(135, 146).  However, several studies have reported a considerable between-person 
variation in phytoestrogen intake in Western populations (121, 147).  This suggests that it 
is feasible to investigate the effect of phytoestrogens on health and disease in non-Asian 
countries.  Several studies have shown that urinary excretion of phytoestrogens is a 
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reliable biomarker of phytoestrogen intake (131, 148), as evidenced by a statistically 
significant correlation between dietary intake of phytoestrogens (particularly from soy 
products) and their urinary excretion (149).  To date, no epidemiologic studies have 
evaluated the associations between phytoestrogen intake and total cancer, cardiovascular, 
and all-cause mortality in a national representative sample of the US population.  
Therefore, the present study investigated this research question using data on urinary 
excretion of total and individual phytoestrogens as well as total cancer, cardiovascular, 
and all-cause mortality, previously collected from the continuous National Health and 
Nutrition Examination Survey (NHANES). 
Subjects and Methods 
Study Population 
Data analyzed in this study were obtained from the NHANES for the years 1999-
2004 and the NHANES linked mortality public-use file.  The mortality file was created 
from a follow-up study of mortality that matched records from the individual years of the 
NHANES study with data in the National Death Index (NDI) through December 31, 2006 
(150).  These data sources were selected because urinary phytoestrogen data for this six-
year period only have been linked to mortality data in the NDI.  NHANES is an annual 
cross-sectional study initiated in 1999 by the Center for Disease Prevention and Control 
(CDC) to assess the health and nutritional status of the general US population.  Data 
collection and sampling procedures for NHANES have been described in detail 
elsewhere (151).  Sample weights were applied to the data through the calculation of a 
six-year weight variable according to the guidelines from the National Center for Health 
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Statistics (NCHS) when combining two or more two-year cycles of the continuous 
NHANES data to produce an unbiased national estimate. 
From 1999 to 2004, a total of 29,402 individuals enrolled in the NHANES also 
completed the interview and health examination components.  As the objective of the 
present study is to investigate urinary phytoestrogens in relation to cancer, 
cardiovascular, and all-cause mortality, our analyses were confined to subjects who were 
≥18 years and completed the 24-hour dietary recall, reducing the sample size to 17,061.  
Urinary concentrations of phytoestrogens were measured among approximately one-third 
of total NHANES participants.  Subsampling in NHANES was performed to reduce 
participant burden and facilitate scheduling and completion of examinations.  All subjects 
in the subsample were randomly selected from the pool of total participants to obtain a 
nationally representative sample, with subsample weights calculated to account for the 
probability of being selected into the subsample and additional non-response (152).  
Excluding subjects without data on urinary phytoestrogens left the cohort with 5,179 
subjects, from whom 79 cancer deaths, 108 cardiovascular deaths, and 290 all-cause 
deaths were identified during a mean follow-up of approximately five years (1999-2006).  
The de-identified data analyzed in the present study are freely available in public 
domains, and the approval for such data analysis by the Institutional Review Board of 
Indiana University was sought but determined not to be applicable. 
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Baseline Data Collection 
NHANES participants were interviewed to collect data on age, sex, race (non-
Hispanic white, non-Hispanic black, and other race including multiracial), marital status 
(married or living with partner, widowed, divorced, or separated, and never married), and 
education level (less than high school, high school graduate or equivalent, and more than 
high school).  Data were also collected on smoking status [never smokers (smoking 0 or 
<100 cigarettes in lifetime), former smokers (smoking ≥100 cigarettes in lifetime but not 
currently smoking), and current smoker], alcohol consumption (0 drink/week, <1 
drink/week, and >1 drink/week), and nutrient intake through a 24-hour food recall.  Body 
mass index (BMI) (kg/m2) was calculated from height and weight measured during the 
medical examination portion of data collection. 
 
Urinary Phytoestrogen Measurement 
Phytoestrogen biomonitoring was accomplished by measuring urinary excretion of 
isoflavones (including daidzein, genistein, equol, and O-desmethylangolensin) and 
lignans (including enterodiol, and enterolactone) using high performance liquid 
chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection (153).  The 
methods for the collection and analysis of urine samples for phytoestrogen concentrations 
have been described in detail elsewhere (154).  Briefly, spot urine specimens were 
collected at the Mobile Examination Centers the morning after a recommended fast, 
processed, stored at -200C, and then shipped to the Division of Environmental Health 
Laboratory Sciences at the NCHS for analysis.  Urine samples were amended with stable 
isotope-labeled internal standards to improve method accuracy and precision, incubated 
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with a deconjugation enzyme to allow the quantification of individual phytoestrogens, 
extracted using solid phase extraction to remove interferences and improve sensitivity, 
and then analyzed using negative ion mode electrospray ionization HPLC-MS/MS, an 
assay with a high degree of specificity for each analyte (154). 
 
Mortality Follow-up 
 International Classification of Diseases 10th Revision (ICD-10) codes were used in 
the selected databases that recorded cause-specific deaths ascertained during follow-up 
through December 31, 2006 (150).  The underlying causes of death were grouped 
according to the guidelines provided by the NCHS.  The primary outcomes of the present 
study were cancer mortality (ICD-10 codes, C0-C97), cardiovascular mortality (ICD-10 
codes, I00-I99), and all-cause mortality (155). 
 
Statistical analysis 
The study population was divided into tertiles based on individuals’ urinary 
concentrations of both total and each individual phytoestrogen to allow for an adequate 
number of subjects in each group.  Total phytoestrogens were calculated by summing up 
all of the individual phytoestrogens, with a similar calculation completed for both total 
isoflavones and total lignans.  Demographic, anthropometric, and lifestyle characteristics 
of subjects (including age, gender, race, BMI, education, smoking status, and alcohol 
intake) were compared by the tertiles of total urinary phytoestrogens (ng/ml) (tertile 1: 4 
– 414; tertile 2: 415 – 1,047; tertile 3: 1,048 – 112,457).  Chi-square tests and analysis of 
variance were employed to compare differences in categorical and continuous variables 
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among tertiles, respectively.  Urinary concentrations of total and individual 
phytoestrogens were summarized by medians and interquartile ranges.  Two-sided t-tests 
were used to compare them between groups using log-transformed values to account for 
skewed distributions. 
Cox proportional hazards regression was performed to calculate hazard ratios (HRs) 
and 95% confidence intervals (CIs) for cancer, cardiovascular, and all-cause mortality in 
relation to urinary phytoestrogens.  The lowest tertile of urinary concentration was the 
reference group to estimate HRs and 95% CIs for two upper tertiles.  The variables 
adjusted in the multivariable models were age, BMI, education, smoking status, total 
energy intake, sodium intake, and urinary creatinine.  No interactions were found to be 
statistically significant, and thus no interaction terms were included in the final model.  
Factors that were tested for their interactions with urinary phytoestrogens in relation to 
each of the three outcomes included age, gender, BMI, education, smoking status, total 
energy intake, and sodium intake.  Gender, race, marital status, and intake of alcohol, fat, 
and calcium were examined as potential confounders but not included in the final models 
because they were not statistically significant or did not substantively alter risk estimates 
(<10%).  Two-sided p-values of <0.05 were considered statistically significant.  SAS 
version 9.4 (Cary, NC) was used for all statistical analyses. 
 Results 
Characteristics of study subjects are shown in Table 1.  Subjects were statistically 
significantly different across total phytoestrogen tertiles for gender, race, education, 
smoking status, and alcohol intake.  Those in the highest tertile of urinary phytoestrogens 
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were more likely to be male, non-Hispanic white, have more years of education, and be 
never smokers, but were less likely to be obese and non-drinkers.   
Table 2 shows differences in urinary concentrations of total and individual 
phytoestrogens between subjects who died of total cancer, cardiovascular disease, and all 
causes with those who remained alive during follow up through the censor date 
(December 31, 2006).  The median urinary concentrations of total phytoestrogens were 
lower in cases of death from each of the three outcomes examined than respective non-
cases.  Similarly, lower urinary concentrations of total lignans were observed for cases of 
death from cardiovascular disease and all causes, and lower urinary levels of 
enterolactone were found for cases of death from all causes.  Conversely, the median 
urinary concentrations of total isoflavones and daidzein were higher among subjects who 
died of cardiovascular disease and all causes than those who remained alive.  No 
significant differences in log-transformed means of total and individual phytoestrogens 
existed between cases of death and non-cases for each of the three outcomes of interest.   
Risk estimates for each of three outcomes examined in relation to urinary excretion of 
total and individual phytoestrogens are presented in Tables 3, 4, and 5.  After adjustment 
for confounders, total phytoestrogens and each individual phytoestrogen were not 
associated with a significantly altered risk of death from total cancers.  A significantly 
increased risk of death from cardiovascular disease was found for higher urinary 
excretion of isoflavones (HR for tertile 3 vs. tertile 1: 2.14; 95% CI: 1.03, 4.47) and 
urinary daidzein (HR for tertile 3 vs. tertile 1: 2.05; 95% CI: 1.02, 4.11).  Conversely, 
higher lignan excretion was significantly associated with a reduced risk of death from 
cardiovascular disease (HR for tertile 3 vs. tertile 1: 0.48; 95% CI: 0.24, 0.97).  Similarly, 
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a significantly reduced all-cause mortality was found for higher urinary excretion of total 
lignans (HR for tertile 3 vs. tertile 1: 0.65; 95% CI: 0.43, 0.96) and enterolactone (HR for 
tertile 3 vs. tertile 1: 0.65; 95% CI: 0.44, 0.97).  
All models met the proportional hazard assumption except for the model constructed 
for urinary enterodiol and cardiovascular mortality.  Their association was evaluated by 
adding an interaction term between enterodiol and the log of time.  Consequently, risk for 
subjects in the second tertile was not statistically significant, but risk for those in the third 
tertile attained significance level.  The addition of the interaction term showed a 
promoting effect of enterodiol on cardiovascular mortality at a follow-up time of ≤19.9 
months, but a protective effect at >19.9 months.  
To evaluate the possibility of reverse causality arising from preexisting chronic 
diseases, additional analyses were performed by removing individuals from the dataset 
who died within two years of enrollment into the study (156, 157).  An increased risk of 
cancer death was observed for subjects in the second tertile of urinary isoflavones (HR: 
2.62; 95% CI: 1.13, 6.10), but risk estimates for all other phytoestrogens remained 
insignificant.  An increased risk of cardiovascular death persisted for subjects in the third 
tertile of urinary isoflavones (HR: 2.79; 95% CI: 1.10, 7.06), but an increased risk for 
individuals in the third tertile of urinary daidzein and a decreased risk for those in the 
third tertile of urinary lignans (HR: 0.39; 95% CI: 0.15, 1.00) were no longer significant. 
The reduced risk of all-cause mortality disappeared for subjects in the third tertile of 
urinary lignans and the third tertile of urinary enterolactone. 
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Discussion 
The present study investigated the associations between urinary phytoestrogens and 
cancer, cardiovascular, and all-cause mortality using data collected from a nationally 
representative sample of the US population.  It was found that urinary concentrations of 
total lignans were significantly and inversely associated with cardiovascular and all-cause 
mortality, whereas urinary concentrations of total isoflavones and daidzein were 
significantly and positively associated with cardiovascular mortality.  In addition, higher 
urinary concentrations of enterolactone was significantly associated with lower all-cause 
mortality. 
Genistein is a main isoflavone present in soy products and has been one of the most 
widely investigated phytoestrogen metabolites.  The present study did not show a 
significant association between urinary genistein and total cancer mortality, which was 
consistent with the results of several other studies in which genistein intake was not 
associated with the risk of different types of cancer (140, 141, 158).  Some studies have 
reported an inverse association between plasma concentrations of genistein and the risk 
of prostate and breast cancers (159, 160).  A few experimental studies revealed a 
protective effect of genistein on prostate cancer (161, 162), whereas another experimental 
study reported an increased risk of colon cancer associated with genistein intake (163).  
In one experiment, Liss et al. found that total phytoestrogens (derived from soy products) 
were more effective than purified genistein on inhibiting the proliferation of prostate 
cancer cell lines.  In that study, genistein was thought to be the major contributor to the 
effect of soy products on cancer cells.  However, gene expression data suggested that 
some interaction existed between genistein and other phytoestrogen compounds available 
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in soy products because genistein alone did not produce the same results (164).  
Collectively, all the studies discussed above suggest that dietary intake of individual 
isoflavones or lignans may exert different effects on individual types of cancer.  Given 
the small number of total cancer deaths (n=79) in the present study, it was not possible to 
examine cancer-specific associations with total and individual phytoestrogens, an 
intriguing question worthy of investigation in cohort studies with a larger number of 
cases of common cancers.  
Enterolactone is a main lignan metabolite in both urine and blood (131).  The 
concentrations of this metabolite were found to reflect the habitual dietary intake of plant 
lignans (129).  As the precursors of enterolactone are detected in whole-grain products, 
legumes, seeds, fruits, and vegetables, the urinary concentrations of enterolactone are 
considered a biomarker for an overall healthy diet (140).  The present study showed low 
all-cause mortality associated with elevated urinary excretion of both total lignans and 
enterolactone.  The consumption of lignan-rich foods has been associated with a 
decreased risk of breast and prostate cancers in some studies (135) and an increased risk 
of prostate cancer in other studies (165).  The present study did not show a significant 
association between urinary excretion of total or individual lignans and total cancer 
mortality.  It has been found that enterolactone suppressed the proliferation and migration 
of prostate cancer cells (166), which suggests that enterolactone intake may reduce the 
risk of prostate and some other cancers.  The differential effects of enterolactone intake 
on the risk of different sites of cancer (135, 165) may account in part for the null results 
observed for this compound in relation to total cancer mortality in the present study.  A 
significantly reduced risk of cardiovascular death associated with urinary excretion of 
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lignans was observed in the present study, which partially contributes to its inverse 
association with all-cause mortality. 
Experimental and epidemiologic data are scarce examining the influence of intake of 
total and individual phytoestrogens on cardiovascular health and disease.  One study 
showed that a lignan-rich diet was associated with elevated high-density lipoprotein 
(HDL) concentrations and reduced triglyceride concentrations among US adults (167).  
As expected, increased serum concentrations of enterolactone have been associated with 
a reduced risk of acute coronary events and death from cardiovascular disease (168, 169).  
The results from these previous studies are consistent with those of the present study.  
Additionally, the present study showed an increased risk of cardiovascular death 
associated with urinary excretion of total isoflavones and daidzein.  The results of 
previous studies on these associations are conflicting.  A placebo-controlled, double-
blinded trial of postmenopausal women supplemented with isoflavone soy protein 
showed no statistically significant effect on atherosclerosis progression (170).  Similarly, 
a meta-analysis of randomized controlled trials revealed that isoflavone supplementation 
did not improve endothelial function in postmenopausal women with high baseline flow-
mediated dilation levels, but significant benefits were found for those with low baseline 
flow-mediated levels (171).  A cross-sectional study on middle-aged men in the US 
reported that usual intakes of isoflavones were not associated with a favorable 
cardiovascular risk profile (172).  A protective or null effect of isoflavones on 
cardiovascular disease that was observed in previous studies was inconsistent with a 
deleterious effect that was found in the present study.  This difference might arise from 
two reasons: 1) most previous studies have focused on postmenopausal women; 2) in 
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those studies, indicators of cardiovascular functions or biomarkers of cardiovascular 
lesions were examined; instead, the present study evaluated urinary excretion of total 
isoflavones and daidzein in relation to cardiovascular mortality among adult women and 
men of all ages.  
 The present study has several advantages.  Exposure to total and individual 
phytoestrogens was evaluated by measuring their concentrations in spot urine.  Urinary 
excretion of phytoestrogens is free of recall bias inherent in food frequency 
questionnaires and is an integrated reflection of phytoestrogen intakes from all sources, 
including those that may be inadequately represented in food composition databases.  For 
example, the most abundant sources of isoflavones in the diet are from foods containing 
soy products, such as tofu.  However, soy additives are found in some processed foods 
(173), and certain isoflavones are naturally present in lower concentrations in other foods 
such as vegetables (174), fruits, and nuts (175).  Another theoretical advantage of 
measuring urinary phytoestrogens is that this assay can also capture phytoestrogen 
metabolites (e.g. equol and O-desmethylangolensin) produced by intestinal bacteria (71).  
It is critical to determine amounts of exposure to specific phytoestrogens because they 
differ in their levels of biological activity (135).  Most food composition databases have 
insufficient data on individual phytoestrogens and their metabolites, which make it 
difficult to reliably quantify intake of these bioactive compounds using food frequency 
questionnaires.  Most previous investigations of the effect of phytoestrogens on cancer 
risk were small case-control studies (165, 176).  Another strength of the present study is 
that the analysis prospectively evaluated association between urinary phytoestrogens and 
all-cause and cause-specific mortality.  The data used are based on a nationally 
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representative sample with a relatively large between-person variation in urinary 
excretion of individual and total phytoestrogens. 
  Limitations of the present study need to be considered in the interpretation of 
obtained results.  A small number of events for both cancer mortality and cardiovascular 
mortality did not allow us to perform a stratified analysis by type of cancer or 
cardiovascular disease.  Future studies that incorporate a longer follow-up period may 
provide new insights into the etiology of cancers and cardiovascular diseases.  Spot urine 
was used to determine phytoestrogen concentrations, and the results of these 
measurements might be different from those using 24-hour urine due to potential 
circadian rhythm.  To adjust for variation in urine dilution, the phytoestrogen 
concentrations were normalized to urinary creatinine, a commonly used method (148, 
177), because creatinine is excreted by glomerular filtration at a relatively constant rate 
(178).  There have been no studies examining the correlation between spot and 24-hour 
urinary phytoestrogen concentrations.  However, phytoestrogen concentrations, 
particularly individual isoflavones, in spot urine have been reported to be statistically 
significantly correlated with their concentrations measured in serum (179).  In addition, 
urinary biomarkers of phytoestrogens were measured only once, and a single 
measurement might not accurately reflect individuals’ usual dietary intake due to within-
person variation.  To capture habitual intake of phytoestrogens, repeated measurements 
of urinary excretion of this family of chemicals may be necessary, but data on such 
repeated measurements are not available from NHANES due to feasibility limitations. 
 As data on dietary intake of phytoestrogens were not available from NHANES, it 
was not possible to determine the correlation between urinary phytoestrogens and their 
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dietary intake.  Significant associations of urinary excretion of daidzein and total lignans 
with cardiovascular and/or all-cause mortality disappeared after excluding cases of death 
that occurred within two years of enrollment, which suggests that these associations 
reported in Tables 4 and 5 may be partially ascribed to reverse causality.  Mortality data 
were analyzed in the present study.  Therefore, obtained results may be less relevant to 
the etiology of total cancer and cardiovascular diseases than those from analysis of 
incidence data.  This is because mortality of these two outcomes may be influenced by 
differences in access to and quality of medical treatment among study subjects. 
It is possible that the effect of phytoestrogens on cancer and cardiovascular disease 
risk differs by metabolic phenotype.  Equol is a metabolite of daidzein and is considered 
to be the most biologically active phytoestrogen among soybean-derived isoflavones 
(180).  It has been found that 30% to 50% of humans are capable of producing this 
metabolite (129), although there is still no consensus on the definition of the producers of 
this compound (129, 181).  Previous studies have yielded mixed results on the association 
between equol-producing status (measured in plasma) and prostate cancer risk.  A 
significantly reduced risk of total prostate cancer was observed among individuals who 
produced high amounts of equol (158, 159), but this finding was not confirmed in other 
studies (176, 182).  It was not possible to evaluate the risk of death from total cancer and 
cardiovascular disease by equol-metabolizing phenotypes due to relatively small sample 
size in the present study. 
In summary, the present study suggests that higher urinary concentrations of total 
lignans were associated with a reduced risk of death from cardiovascular disease.  
Similarly, elevated urinary concentrations of both total lignans and enterolactone were 
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associated with low all-cause mortality.  Conversely, higher urinary concentrations of 
total isoflavones and daidzein were significantly associated with an increased risk of 
death from cardiovascular disease.  It is important and timely to further investigate the 
associations of phytoestrogen intake, its biomarkers, and metabolic polymorphisms with 
the risk of total cancer, specific cancers, and cardiovascular disease in large prospective 
cohort studies, as data generated from such studies may offer innovative avenues for the 
prevention of these major diseases among people across the world. 
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Table 1: Baseline characteristics of subjects by tertiles of urinary excretion of total 
phytoestrogens (ng/mL) in the continuous National Health and Nutrition Examination 
Survey, 1999-2004 
 Total Phytoestrogens (ng/mL)  
 Tertile 1 Tertile 2 Tertile 3  
Characteristics (4 - 414) (415 - 1,047) (1,048 - 112,457)  
 n = 1,726 n = 1,727 n = 1,726 p-value 
Age [Mean (SD)] 44.7 (16.8) 45.5 (17.9) 44.8 (17.4) 0.28 
Gender (%)     
  Male 45.9 47.2 51.0 0.006 
  Female 54.1 52.8 49.0  
Race/Ethnicity (%)     
  Non-Hispanic White 70.7 71.2 72.5 0.029 
  Non-Hispanic Black 9.9 11.8 11.7  
  Other   19.4 17.0 15.8  
BMI1 [Mean (SD)] 28.3 (6.4) 28.2 (5.9) 27.7 (6.4) 0.004 
Education (%)     
  Less than High School 23.1 20.7 19.5 <0.001 
  High School Graduate 
or Equivalent 27.3 27.5 22.9  
More than High 
School 49.6 51.8 57.6  
Smoking Status (%)     
  Never Smoker 48.2 51.4 53.6 <0.001 
  Former Smoker 22.9 24.1 25.3  
  Current Smoker 28.9 24.5 21.1  
Alcohol Intake (%)     
  0 drinks/week 20.2 21.0 16.7 0.025 
  < 1 drinks/week 41.9 42.9 46.1  
  > 1 drinks/week 37.9 36.2 37.3  
1 Body Mass Index. 
 
 
 
65 
 
 Table 2: Differences in urinary concentrations of total and individual phytoestrogens (ng/mL) between subjects who did and did not die from total 
cancer, cardiovascular disease, or all-causes in the continuous National Health and Nutrition Examination Survey, 1999-20041 
  Total Cancer Cardiovascular Diseases All Causes 
  Cases of Deaths          Non-Cases Cases of Deaths Non-Cases Cases of Deaths Non-Cases 
Phytoestrogens (n = 79) (n = 5,100) (n = 108) (n = 5,071) (n = 290) (n = 4,889) 
Total Phytoestrogens 607 (416, 1311) 679 (306, 1440) 437 (268, 1083) 682 (308, 1442) 531 (294, 1117) 687 (308, 1453) 
Isoflavones 160 (67, 294) 114 (44, 345) 163 (62, 260) 114 (44, 346) 139 (54, 286) 113 (44, 346) 
Genistein 32 (13, 88) 26 (9, 89) 28 (13, 79) 26 (9, 90) 31 (12, 79) 26 (9, 90) 
Daidzein 78 (28, 170) 56 (18, 191) 84 (32, 143) 56 (18, 191) 68 (21, 167) 56 (18, 191) 
Equol 8 (3, 19) 8 (2, 17) 6 (3, 14) 8 (2, 17) 7 (3, 18) 8 (2, 17) 
O-desmethylangolensin 3 (0, 16) 4 (1, 19) 5 (1, 21) 4 (1, 19) 3 (1, 16) 4 (1, 19) 
Lignans 437 (213, 809) 415 (148, 928) 299 (124, 706) 416 (149, 931) 347 (152, 750) 417 (148, 940) 
Enterodiol 53 (18, 112) 39 (14, 92) 32 (16, 66) 40 (14, 93) 33 (15, 86) 40 (14, 93) 
Enterolactone 371 (171, 743) 347 (104, 821) 240 (75, 622) 349 (105, 824) 289 (124, 628) 351 (104, 825) 
1 Values are medians (interquartile ranges).  
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Table 3: HRs (95% CIs) for total cancer mortality by tertiles of urinary concentrations 
of total and individual phytoestrogens in the continuous National Health and Nutrition 
Examination Survey, 1999-2004 
  Cancer Mortality 
Phytoestrogens (ng/mL) No. of Cases 
Person- 
Years 
Creatinine-
Adjusted HR 
(95% CI)1 
Multivariable-
Adjusted HR          
(95 % CI)2 
Total Phytoestrogens     
T1 (4-14) 25 1,820 Reference Reference 
T2 (415-1,047) 27 1,906 1.76 (0.93, 3.35) 1.41 (0.72, 2.75) 
T3 (1,048-112,457) 27 1,823 1.36 (0.68, 2.71) 1.18 (0.57, 2.46) 
p-trend   0.73 0.90 
Isoflavones     
T1 (1-58) 20 1,451 Reference Reference 
T2 (59-219) 30 2,081 1.96 (1.00, 3.87) 1.94 (0.96, 3.95) 
T3 (220-55,729) 29 2,017 1.62 (0.80, 3.30) 1.67 (0.79, 3.52) 
p-trend   0.61 0.56 
Genistein     
T1 (0-13) 22 1,606 Reference Reference 
T2 (14-54) 25 1,765 1.57 (0.81, 3.06) 1.44 (0.73, 2.87) 
T3 (55-25,700) 32 2,178 1.70 (0.88, 3.31) 1.46 (0.73, 2.93) 
p-trend   0.23 0.51 
Daidzein     
T1 (0-25) 20 1,441 Reference Reference 
T2 (26-115) 29 2,098 1.41 (0.72, 2.78) 1.29 (0.64, 2.63) 
T3 (116-29,200) 30 2,010 1.68 (0.86, 3.29) 1.77 (0.90, 3.49) 
p-trend   0.18 0.11 
Equol     
T1 (0-3) 22 1,532 Reference Reference 
T2 (4-11) 24 1,722 0.96 (0.48, 1.92) 0.94 (0.46, 1.91) 
T3 (12-17,200) 27 1,927 1.12 (0.58, 2.19) 1.12 (0.55, 2.27) 
p-trend   0.67 0.69 
O-desmethylangolensin     
T1 (0-1) 29 2,124 Reference Reference 
T2 (2-9) 25 1,730 0.91 (0.49, 1.71) 0.78 (0.41, 1.48) 
T3 (10-9,890) 23 1,569 0.83 (0.44, 1.56) 0.75 (0.38, 1.48) 
p-trend   0.59 0.58 
Lignans     
T1 (0-225) 27 1,999 Reference Reference 
T2 (226-691) 30 2,116 1.68 (0.90, 3.13) 1.43 (0.75, 2.73) 
T3 (692-85,847) 22 1,434 1.22 (0.62, 2.39) 1.05 (0.52. 2.14) 
p-trend   0.87 0.86 
Enterodiol     
T1 (0-20) 27 1,991 Reference Reference 
T2 (21-63) 22 1,586 0.94 (0.47, 1.88) 1.09 (0.54, 2.22) 
T3 (64-18,000) 28 1,835 1.60 (0.85, 3.01) 1.66 (0.85, 3.34) 
p-trend   0.08 0.10 
Enterolactone     
T1 (0-173) 25 1,790 Reference Reference 
T2 (174-595) 32 2,330 1.77 (0.96, 3.29) 1.52 (0.80, 2.90) 
T3 (596-85,300) 22 1,429 1.19 (0.60, 2.32) 1.01 (0.50, 2.05) 
p-trend   0.99 0.72 
1Adjusted for urinary creatinine 
2Adjusted for age, education, smoking status, body mass index, total energy intake, sodium intake, and 
urinary creatinine 
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Table 4: HRs (95% CIs) for cardiovascular mortality by tertiles of urinary 
concentrations of total and individual phytoestrogens in the continuous National 
Health and Nutrition Examination Survey, 1999-2004 
  Cardiovascular Mortality 
Phytoestrogens (ng/mL) No. of Cases 
Person- 
Years 
Creatinine-
Adjusted HR   
(95% CI)1 
Multivariable-
Adjusted HR          
(95 % CI)2 
Total Phytoestrogens     
T1 (4-14) 42 3,035 Reference Reference 
T2 (415-1,047) 37 2,819 0.83 (0.47, 1.49) 0.58 (0.31, 1.09) 
T3 (1,048-112,457) 29 2,231 0.80 (0.42, 1.53) 0.63 (0.31, 1.28) 
p-trend   0.55 0.36 
Isoflavones     
T1 (1-58) 31 2,346 Reference Reference 
T2 (59-219) 37 2,698 2.07 (1.09, 3.92) 1.97 (0.98, 3.97) 
T3 (220-55,729) 40 3,041 1.96 (1.01, 3.82) 2.14 (1.03, 4.47) 
p-trend   0.21 0.15 
Genistein     
T1 (0-13) 33 2,455 Reference Reference 
T2 (14-54) 38 2,828 1.76 (0.95, 3.24) 1.59 (0.83, 3.06) 
T3 (55-25,700) 37 2,802 1.70 (0.89, 3.22) 1.39 (0.69, 2.80) 
p-trend   0.28 0.68 
Daidzein     
T1 (0-25) 30 2,265 Reference Reference 
T2 (26-115) 38 2,819 1.66 (0.88, 3.15) 1.48 (0.74, 2.97) 
T3 (116-29,200) 40 3,001 1.96 (1.02, 3.74) 2.05 (1.02, 4.11) 
p-trend   0.10 0.06 
Equol     
T1 (0-3) 36 2,629 Reference Reference 
T2 (4-11) 35 2,598 1.24 (0.67, 2.27) 1.40 (0.72, 2.74) 
T3 (12-17,200) 29 2,220 0.95 (0.48, 1.86) 1.22 (0.57, 2.60) 
p-trend   0.71 0.78 
O-desmethylangolensin     
T1 (0-1) 32 2,374 Reference Reference 
T2 (2-9) 28 2,066 1.15 (0.60, 2.19) 1.07 (0.53, 2.15) 
T3 (10-9,890) 40 3,025 1.50 (0.81, 2.77) 1.71 (0.87, 3.35) 
p-trend   0.19 0.07 
Lignans     
T1 (0-225) 40 2,858 Reference Reference 
T2 (226-691) 39 3,009 0.83 (0.47, 1.46) 0.55 (0.30, 1.02) 
T3 (692-85,847) 29 2,218 0.73 (0.39, 1.38) 0.48 (0.24, 0.97) 
p-trend   0.36 0.07 
Enterodiol     
T1 (0-20) 38 2,805 Reference Reference 
T2 (21-63) 38 2,961 1.15 (0.65, 2.04) 1.36 (0.74, 2.48) 
T3 (64-18,000) 30 2,177 0.92 (0.48, 1.77) 0.71 (0.87, 1.78) 
p-trend   0.69 0.52 
Enterolactone     
T1 (0-173) 40 2,880 Reference Reference 
T2 (174-595) 37 2,837 0.98 (0.56, 1.72) 0.68 (0.37, 1.26) 
T3 (596-85,300) 31 2,368 0.78 (0.41, 1.48) 0.54 (0.27, 1.07) 
p-trend   0.43 0.10 
1Adjusted for urinary creatinine 
2Adjusted for age, education, smoking status, body mass index, total energy intake, sodium intake, and 
urinary creatinine 
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Table 5: HRs (95% CIs) for all-cause mortality by tertiles of urinary concentrations of 
total and individual phytoestrogens in the continuous National Health and Nutrition 
Examination Survey, 1999-2004 
  All-Cause Mortality 
Phytoestrogens (ng/mL) No. of Cases 
Person- 
Years 
Creatinine-
Adjusted HR   
(95% CI)1 
Multivariable-
Adjusted HR          
(95 % CI)2 
Total Phytoestrogens     
T1 (4-14) 102 7,250 Reference Reference 
T2 (415-1,047) 100 7,269 1.06 (0.76, 1.47) 0.78 (0.55, 1.12) 
T3 (1,048-112,457) 88 6,263 0.87 (0.60, 1.25) 0.69 (0.46, 1.02) 
p-trend   0.36 0.09 
Isoflavones     
T1 (1-58) 87 6,332 Reference Reference 
T2 (59-219) 100 7,119 1.46 (1.03, 2.08)* 1.34 (0.93, 0.95) 
T3 (220-55,729) 103 7,331 1.26 (0.87, 1.83) 1.22 (0.82, 1.82) 
p-trend   0.69 0.71 
Genistein     
T1 (0-13) 87 6,325 Reference Reference 
T2 (14-54) 97 6,968 1.60 (1.13, 2.28)* 1.44 (1.00, 2.08) 
T3 (55-25,700) 106 7,489 1.44 (1.00, 2.08) 1.17 (0.79, 1.74) 
p-trend   0.31 0.97 
Daidzein     
T1 (0-25) 82 5,948 Reference Reference 
T2 (26-115) 101 7,384 1.23 (0.86, 1.77) 1.09 (0.74, 1.60) 
T3 (116-29,200) 107 7,450 1.44 (1.01, 2.07)* 1.43 (0.98, 2.08) 
p-trend   0.07 0.47 
Equol     
T1 (0-3) 93 6,666 Reference Reference 
T2 (4-11) 86 6,222 1.01 (0.70, 1.46) 1.06 (0.72, 1.56) 
T3 (12-17,200) 86 6,067 1.07 (0.74, 1.55) 1.18 (0.79, 1.76) 
p-trend   0.71 0.42 
O-desmethylangolensin     
T1 (0-1) 91 6,630 Reference Reference 
T2 (2-9) 91 6,375 1.24 (0.87, 1.77) 1.12 (0.77 - 1.62) 
T3 (10-9,890) 93 6,725 1.13 (0.79, 1.63) 1.12 (0.76, 1.65) 
p-trend   0.90 0.72 
Lignans     
T1 (0-225) 101 7,106 Reference Reference 
T2 (226-691) 112 8,281 1.26 (0.91, 1.74) 0.99 (0.70, 1.40) 
T3 (692-85,847) 77 5,395 0.86 (0.60, 1.25) 0.65 (0.43, 0.96) 
p-trend   0.26 0.019 
Enterodiol     
T1 (0-20) 105 7,566 Reference Reference 
T2 (21-63) 93 6,877 0.92 (0.65, 1.29) 1.05 (0.73, 1.50) 
T3 (64-18,000) 88 6,060 0.97 (0.68, 1.37) 0.98 (0.67, 1.43) 
p-trend   0.95 0.85 
Enterolactone     
T1 (0-173) 102 7,177 Reference Reference 
T2 (174-595) 110 8,141 1.34 (0.97, 1.85) 1.09 (0.77, 1.54) 
T3 (596-85,300) 78 5,464 0.86 (0.59, 1.25) 0.65 (0.44, 0.97) 
p-trend   0.22 0.014 
1Adjusted for urinary creatinine 
2Adjusted for age, education, smoking status, body mass index, total energy intake, sodium intake, and 
urinary creatinine 
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Chapter 3 
 
Dietary Intake of Phytoestrogens and the Risk of Prostate Cancer in the Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) 
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Abstract 
Background: Prostate cancer is the most common non-cutaneous cancer and second 
leading cause of cancer death among men in the US.  However, no effective preventive 
measures are available as few modifiable risk factors have been identified. 
Objective: The present study aimed to investigate the associations between dietary intake 
of total and individual phytoestrogens and the risk of total and advanced prostate cancer 
among 30,097 participants in the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (PLCO).   
Design: During a median follow up of 11.5 years, 3,628 cases of prostate cancer 
(including 396 advanced cases) have been identified from 30,097 men.  Dietary intake of 
phytoestrogens was assessed with a validated food frequency questionnaire.  Cox 
proportional hazards regression was performed to estimate hazard ratios (HRs) and 95% 
confidence intervals (CI) for dietary phytoestrogens in relation to prostate cancer risk.   
Results: An increased risk of advanced prostate cancer was found for  the dietary intake 
of isoflavones (HR for quintile 5 vs. quintile 1: 1.58; 95% CI: 1.11, 2.24), genistein (HR 
for quintile 4 vs. quintile 1: 1.42; 95% CI: 1.02, 1.98), daidzein (HR for quintile 5 vs. 
quintile 1: 1.62; 95% CI: 1.13, 2.32) and glycitein (HR for quintile 5 vs. quintile 1: 1.53; 
95% CI: 1.09, 2.15).  Conversely, dietary intake of genistein was associated with a 
reduced risk of non-advanced prostate cancer (HR for quintile 5 vs. quintile 1: 0.88; 95% 
CI: 0.78, 0.99) and total prostate cancer (HR for quintile 3 vs. quintile 1: 0.90; 95% CI: 
0.81, 1.00).   
71 
 
Conclusion: This national prospective cohort study revealed that dietary isoflavone 
intake modulated the risk of prostate cancer, and that this effect may differ by the 
aggressiveness of the disease. 
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Introduction 
Primary prevention of chronic diseases such as cancer is one of the major goals of 
public health.  Prostate cancer is the most common non-cutaneous cancer and the second 
leading cause of cancer death among men in the US, with 238,590 new cases and 29,720 
deaths estimated to occur in 2013 (183).  Most risk factors identified to date are non-
modifiable, such as age, ethnicity, and family history (184).  A modifiable factor that is 
potentially protective for prostate cancer but has not yet been well explored in the US 
population is dietary intake of total and individual phytoestrogens.  
Phytoestrogens are a group of non-steroidal plant metabolites that abound in soy 
products, legumes, and chick peas (185, 186).  Individual phytoestrogens that exist in 
these food products include genistein, daidzein, and glycitein (187), and to a lesser 
degree, formononetin, biochanin A, and coumestrol (54).  Experimental studies suggest 
that phytoestrogen intake may modulate the risk of certain types of cancer (134, 135) due 
to their structural similarity to 17β-estradiol (188) and the resulting competitive binding 
to estrogen receptors (136, 189).  Of particular relevance to prostate carcinogenesis, 
animal studies have shown that phytoestrogens reduce serum testosterone levels in rats 
(190, 191).  As a significant positive association between serum testosterone and prostate 
cancer risk has been consistently reported in epidemiologic studies (192, 193), the results 
of these animal studies suggest that it is biologically plausible that high intake of 
phytoestrogens may reduce the risk of this malignancy. 
Despite experimental evidence, it is still not clear whether there is an association 
between phytoestrogen intake and prostate cancer risk in Western populations.  Results of 
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a few previous studies on this topic have been discrepant (103, 194).  Despite a low 
average consumption of soy products in Western countries (195, 196), it is still feasible to 
investigate the effect of phytoestrogens on this population because of additional dietary 
sources of phytoestrogens (173-175) leading to a considerable between person variation 
in phytoestrogen intake (121, 197).  To date, no epidemiologic studies have evaluated the 
associations between phytoestrogen intake and the development of total and advanced 
cases of prostate cancer in a large sample of the US population.  Therefore, the present 
study investigated this research question using data on total and individual phytoestrogen 
intake, as well as total and advanced cases of prostate cancer, previously collected from 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). 
Subjects and Methods 
Study Population 
Data analyzed in this study were obtained from the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO).  Approximately 155,000 participants were 
enrolled from 10 medical centers across the US between November 1993 and July 2001 
in the PLCO.  Study participants were followed up through December 31, 2009.  Only 
male participants were eligible for the present study as the outcome of interest was 
prostate cancer.  Further exclusion criteria included participants who did not complete a 
baseline questionnaire, those with a history of cancer, and those without follow-up after 
the enrollment period.  After those exclusions, a total of 30,097 subjects met the 
eligibility criteria for this study.  During a median follow up of 11.5 years, 3,628 cases of 
prostate cancer (including 396 advanced cases) were identified from the 30,097 men.  
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Advanced cases of prostate cancer were defined as stage II prostate cancer with a 
Gleason score of ≥ 8, and all stage III or stage IV cases (198).  The date of randomization 
is considered to be the entry date into the trial (198).  The PLCO is a de-identified, 
publicly released data set and thus it was determined to be exempt from human subjects 
review by the Indiana University IRB. 
 
Data Collection 
All eligible subjects were asked to complete a sex-specific baseline questionnaire and 
a food frequency questionnaire.  The vast majority of (96.8%) of study participants 
completed the baseline questionnaire that solicited information on age, race, BMI, marital 
status, education level, daily physical activity, cigarette smoking, family history of 
prostate cancer, family history of other cancer, aspirin use, ibuprofen use, and vasectomy 
status (198). 
The Dietary Questionnaire (DQX) was offered to the intervention arm participants at 
the time of randomization into the trial.  This 137-item food frequency questionnaire was 
developed to assess usual diet and alcohol consumption during the previous year.  The 
DQX also contained questions on use of vitamins and other dietary supplements.  Dietary 
intake of energy and nutrients were calculated by multiplying the amount of energy and 
nutrients in a standard portion size of each food item by the reported frequency of 
consumption and summing over all food items.  Examples of dietary and nutrient 
variables included total iron intake, caffeine, total dietary energy, processed meat 
consumption, and red meat consumption.  Individual phytoestrogens considered for this 
study included genistein, daidzein, glycitein, coumestrol, formononetin, and biochanin A.  
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Total phytoestrogens were calculated by summing the individual phytoestrogens, with a 
similar calculation performed for total isoflavones.  The nutrient amounts were based on 
values from national dietary databases including the USDA’s Continuing Survey of Food 
Intakes by Individuals and the University of Minnesota’s Nutrition Data Systems for 
Research (198). 
 
Statistical Analysis 
The study population was divided into quintiles for total and each individual 
phytoestrogen.  Demographic, anthropometric, and lifestyle characteristics of subjects 
(including age, race/ethnicity, BMI, education, smoking status, alcohol intake, caffeine 
intake, red meat intake, and family history of prostate cancer) were compared across the 
total phytoestrogen intake (mg/day) quintiles (Q1: 0.0 – 0.29; Q2: 0.30 – 0.50; Q3: 0.51 – 
0.77; Q4: 0.78 – 1.22; Q5: 1.23 – 68.66).  Chi-square tests and analysis of variance 
(ANOVA) were used to compare differences in categorical and continuous variables 
among quintiles, respectively.  Because of non-normal distributions of phytoestrogen 
intake, Wilcoxon Rank-Sum tests were used to make pair-wise comparisons of total and 
individual phytoestrogen intake between subjects with advanced prostate cancer and non-
cases, as well as total subjects with any prostate cancer and non-cases.   
Cox proportional hazards regression was performed to calculate hazard ratios (HRs) 
and 95% confidence intervals (CIs) for prostate cancer risk in relation to dietary 
phytoestrogens.  Each outcome of interest was compared against the remaining total 
population, with no additional cases removed from the comparison.  Separate analyses 
were performed on advanced and non-advanced prostate cancer cases since many non-
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advanced cases would likely not progress into advanced disease.  Dietary intake of total 
phytoestrogens and each individual phytoestrogen were divided into quintiles with the 
lowest quintile as the reference group to estimate HRs and 95% CIs for the upper four 
quintiles.  Covariates in the multivariable models included age, race, BMI, smoking 
status, alcohol intake, and family history of prostate cancer.  Other variables that were 
examined as potential confounders included education, marital status, daily physical 
activity, family history of other cancer, aspirin use, ibuprofen use, vasectomy, dietary 
iron, caffeine intake, dietary energy, processed meat consumption, and red meat 
consumption.  None of these variables were ultimately included in the final model 
because they were not statistically significantly related to prostate cancer or did not 
substantially alter risk estimates (<10%).  Several factors were tested for potential 
interactions with dietary phytoestrogen in relation to the development of prostate cancer, 
including age, race, BMI, education, smoking status, alcohol intake, caffeine intake, red 
meat intake, and family history of prostate cancer.  None of these variables showed a 
statistically significant interaction and were therefore not included in the final model.  All 
models met the assumptions for proportional hazards models.  Additional Cox 
proportional hazards regression analyses were performed after removing subjects from 
the dataset who developed prostate cancer within two-years of enrollment to eliminate 
any effects arising from preexisting, undetected cases of prostate cancer (199, 200).  
SPSS version 20 was used for statistical analysis.  A p-value of <0.05 was considered 
statistically significant.  
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Results 
Characteristics of study subjects are shown in Table 6.  Statistically significant 
differences existed in race, education, smoking status, alcohol intake, and family history 
of prostate cancer across total phytoestrogen quintiles.  Subjects in the highest quintile of 
total dietary phytoestrogens were more likely to be Asian, better educated, and never 
smokers, were less likely to be non-Hispanic White, and had a lower BMI. 
Median levels and interquartile ranges of dietary intake of total and individual 
phytoestrogens (mg/day) were compared between total prostate cancer cases, advanced 
cases, and those who had not developed prostate cancer through the censor date 
(December 31, 2009) (Table 7).  Advanced cases of prostate cancer had statistically 
significantly higher intake of total phytoestrogens, isoflavones, genistein, daidzein, and 
glycitein than non-cases.  Insignificant differences were observed for dietary intake of 
total and individual phytoestrogens between total cases of prostate cancer and non-cases.   
HRs (95% CIs) for each of three prostate cancer outcomes considered in relation to 
dietary intake of total and individual phytoestrogens are presented in Tables 8, 9, and 10.  
After adjustment for confounders, a significantly increased risk of advanced prostate 
cancer was found for dietary intake of total isoflavones (HR for Q5 vs. Q1: 1.58; 95% CI: 
1.11, 2.24), genistein (HR for Q4 vs. Q1: 1.42; 95% CI: 1.02, 1.98), daidzein (HR for Q5 
vs. Q1: 1.62; 95% CI: 1.13, 2.32), and glycitein (HR for Q5 vs. Q1: 1.53; 95% CI: 1.09, 
2.15).  Conversely, dietary intake of genistein was significantly associated with a reduced 
risk of non-advanced prostate cancer (HR for Q5 vs. Q1: 0.88; 95% CI: 0.78, 0.99).   
After removing subjects who developed prostate cancer within two-years of 
enrollment from analysis, an increased risk of advanced prostate cancer appeared for 
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subjects who were in the fifth quintile of total dietary phytoestrogens, and persisted for 
those in the fifth quintile of total dietary isoflavones, the fourth quintile of dietary 
genistein, the second, third, and fifth quintile of dietary daidzein, and the fifth quintile of 
dietary glycitein, but disappeared for those who were in the second quintile of 
formononetin.  In addition, a reduced risk of non-advanced prostate cancer was no longer 
significant for subjects who were in the third and fifth quintile of dietary genistein and in 
the third quintile of dietary genistein in relation to total prostate cancer. 
Discussion 
The present study showed that higher dietary intake of isoflavones, genistein, 
daidzein, glycitein, and formononetin were significantly associated with an increased risk 
of advanced prostate cancer after adjustment for possible confounding variables.  
Conversely, higher dietary intake of genistein was significantly associated with a 
decreased risk of non-advanced prostate cancer and total prostate cancer in a large sample 
of the US population.  The approach of dividing prostate cancer cases into separate 
groups of advanced and non-advanced cases is supported by the growing body of 
evidence that suggests that these different types of prostate cancer may not be 
etiologically similar (124).   
Genistein is one of the most widely investigated phytoestrogen metabolites.  The 
present study showed a significant increased risk between dietary genistein and advanced 
prostate cancer, but a significant decreased risk between dietary genistein and both non-
advanced and total prostate cancer.  The results of decreased risk of non-advanced and 
total prostate cancer are consistent with the findings from other studies that reported an 
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inverse association between plasma concentrations of genistein and the risk of prostate 
cancer (201, 202).  Some experimental studies have also revealed a protective effect of  
genistein on prostate cancer (161, 203), although total phytoestrogens may be more 
effective than genistein alone for  inhibiting the proliferation of prostate cancer (204).  
Recently, one experimental study conducted by Nakamura et al. revealed that genistein 
may play a role in increasing growth factor signaling and promoting tumor progression in 
advanced prostate cancer (84).  In that study, a prostatectomy sample was grafted into 
mice, and increased lymph node and additional organ metastases was observed in the 
genistein-treated group compared with the control group.  Further analysis by Nakamura 
et al. showed that the genistein-treated mice had more proliferating and fewer apoptotic 
cancer cells than the controls, leading to enhanced tumorigenic activity (84).  The 
increased risk between dietary genistein and advanced prostate cancer that was observed 
in the present study has not been reported in other observational studies.  The differences 
might arise from two reasons: 1) many previous studies have focused on Asian 
populations where the intake of phytoestrogens is higher than in Western populations; 2) 
in the other studies, total prostate cancer was examined, conversely in our study, risks 
were examined for advanced and non-advanced disease separately. 
It is remains unclear why genistein simultaneously increased the risk of advanced 
prostate cancer and decreased the risk of non-advanced prostate cancer.  There is a 
biologic plausibility for the increased risk of advanced prostate cancer observed in this 
study.  It has been hypothesized that estrogen may play a role in prostate carcinogenesis 
due to the possible mutagenic effects of estrogen metabolites (205), and phytoestrogens 
can induce estrogenic responses in the body due to their structural similarity to 17β-
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estradiol (12).  In addition, certain repeat polymorphisms in genes involved in estrogen 
synthesis and metabolism have demonstrated an increased risk of prostate cancer, with 
some genotypes showing a significant odds ratio of greater than two for advanced 
prostate cancer (Gleason score ≥ 7).  Interestingly, the largest significantly increased risk 
of advanced prostate was observed in patients who were treated with finasteride, which 
inhibits the conversion of testosterone to dihydrotestosterone, causing an increase of 
estrogen levels (206).  Therefore, it is reasonable to assume that an increased intake of 
phytoestrogens exhibiting increased estrogenic activity would also be associated with an 
increased risk of advanced prostate cancer.  
Daidzein, like genistein, is one of the main isoflavones found in soy products and has 
also been among the most widely investigated.  The current study did not show a 
significant association of dietary daidzein intake with both non-advanced and total 
prostate cancer, which was consistent with the results of several other studies in which 
daidzein intake was not associated with prostate cancer (202, 207, 208).  Two double 
blind, placebo controlled, randomized controlled trials also showed no significant 
association between daidzein supplementation and the risk of prostate cancer (209, 210).  
The increased risk between dietary daidzein and advanced prostate cancer that was seen 
in the present study was not observed in other studies.  Since daidzein along with 
genistein are the two phytoestrogen metabolites found in the highest concentrations in 
commonly eaten foods, it remains biologically plausible that daidzein is also associated 
with an increased risk of advanced prostate cancer because of the estrogenic effects.   
The present study has several advantages.  The large sample size permitted the 
performance of separate analyses for both advanced and non-advanced prostate cancer.  
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The results of these analyses showed clear differences in the effects of phytoestrogens on 
the risk of indolent and aggressive prostate cancer.  The prospective nature of the PLCO 
study largely excluded the possibility of reverse causality between intake of total and 
individual phytoestrogens and the risk of prostate cancer.  Most previous investigations 
of the effect of phytoestrogens on cancer risk were small case-control studies (207, 211-
213), which did not allow for the establishment of the temporal relationship. 
There were several limitations of the present study that should be considered when 
interpreting the obtained results.  Intake of total and individual phytoestrogens was 
estimated using a food frequency questionnaire.  In addition to recall bias occurring in 
questionnaire-based dietary assessment, total amounts of phytoestrogens may be 
inadequately represented in many food composition databases.  Soy additives are found 
in some processed foods (173), and certain isoflavones are naturally present in lower 
concentrations in other foods such as vegetables (214), fruits, and nuts (215).  The 
isoflavones from these food products are most likely to be underrepresented in food 
composition databases.  Another limitation of using a dietary questionnaire as opposed to 
urinary or plasma concentrations is that this method is unable to capture phytoestrogen 
metabolites produced by intestinal bacteria such as equol and O-desmethylangolensin 
(216).  To better evaluate the effects of phytoestrogens on prostate cancer risk, it is 
preferable to assess dietary intake of phytoestrogens and their urinary biomarkers in the 
same populations.  Another strength of utilizing phytoestrogen biomarkers is that they 
differ in their levels of biologic activity (195).  Nevertheless, data on phytoestrogen 
biomarkers are not available from the PLCO study.  
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In summary, the present study suggests that higher dietary intake of isoflavones, 
genistein, daidzein, and glycitein were associated with an increased risk of development 
of advanced prostate cancer.  Conversely, higher dietary intake of genistein was 
associated with a reduced risk of non-advanced, and total prostate cancer.  Since many 
cases of non-advanced prostate cancer will have little impact on the patients’ quality of 
life (217), it is important to determine modifiable factors that may increase the risk of 
advanced prostate cancer.  If results reported in the present study are confirmed in other 
epidemiologic studies, modifying intake of phytoestrogens may offer innovative practical 
avenues for the prevention of prostate cancer. 
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Table 6: Baseline characteristics of study subjects by quintiles of dietary intake of total phytoestrogens 
(mg/day) in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) 
 Total Phytoestrogens (mg/day)  
Characteristics 
Q1             
(0.0 - 0.29) 
Q2            
(0.30 - 0.50) 
Q3           
(0.51 - 0.77) 
Q4           
(0.78 - 1.22) 
Q5           
(1.23 - 68.66)  
n = 6,018 n = 6,023 n = 6,015 n = 6,025 n = 6,016 p-value 
Age [Mean (SD)] 61.7 (5.26) 62.8 (5.24) 63.5 (5.19) 63.0 (5.31) 62.7 (5.35) <0.001 
Race/Ethnicity (%)       
Non-Hispanic White 20.6 20.7 20.7 20.8 17.1 <0.001 
Non-Hispanic Black 25.3 21.5 20.8 16.2 16.1  
Asian 0.7 1.4 2.9 5.1 89.9  
Other   17.4 17.4 15.3 16.6 33.3  
BMI [Mean (SD)] 27.9 (4.20) 27.8 (4.06) 27.7 (4.05) 27.5 (4.09) 27.1 (4.22) <0.001 
Education (%)       
Less than High School 23.9 22.0 22.8 16.7 14.6 <0.001 
High School Graduate 
or Equivalent 25.6 23.2 20.7 16.5 14.2  
Post High School 
Education 20.7 20.9 20.3 19.7 18.4  
College Graduate or 
Higher 16.2 17.6 18.9 22.5 24.8  
Smoking Status (%)       
Never Smoker 17.7 19.0 20.0 21.2 22.2 <0.001 
Former Smoker 26.8 23.1 18.6 17.0 14.4  
Current Smoker 20.3 20.1 20.3 19.8 19.6  
Alcohol Intake (%)       
Drinkers  18.8 19.9 21.0 20.5 19.7 <0.001 
Non-Drinkers l 25.2 20.5 15.3 17.8 21.1  
Caffeine Intake 
(mg/day) [Mean (SD)] 561.6 (665.67) 555.0 (647.55) 550.9 (647.99) 550.2 (629.44) 549.6 (611.52) 0.883 
Red Meat Intake 
(g/day) [Mean (SD)] 40.1 (34.51) 44.3 (36.61) 43.6 (38.85) 44.5 (39.16) 39.6 (40.92) <0.001 
Family History of 
Prostate Cancer       
Yes 18.3 20.5 21.0 21.6 18.6 0.032 
No 20.0 20.0 19.9 19.9 20.2  
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Table 7: Differences in dietary intake of total and individual phytoestrogens (mg/day) between 
subjects who did and did not develop prostate cancer in the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO)1 
Phytoestrogens 
(mg/day) 
Total Cases of 
Prostate Cancer                            
(n = 3,628) 
Advanced 
Prostate Cancer                            
(n = 396) 
Non-Cases                          
(n = 26,469) 
p-value:     
Total Cases 
vs. Non-Cases 
p-value:      
Advanced vs. 
Non-Cases 
Total Phytoestrogens 0.63 (0.35, 1.01) 0.69 (0.40, 1.12) 0.63 (0.34, 1.05) 0.81 0.008 
Isoflavones 0.44 (0.22, 0.75) 0.49 (0.26, 0.83) 0.43 (0.21, 0.76) 0.72 0.002 
Genistein 0.18 (0.05, 0.34) 0.20 (0.07, 0.36) 0.17 (0.05, 0.35) 0.51 0.007 
Daidzein 0.26 (0.15, 0.40) 0.28 (0.17, 0.44) 0.25 (0.14, 0.41) 0.46 0.002 
Glycitein 0.01 (0.00, 0.02) 0.01 (0.00, 0.03) 0.01 (0.00, 0.03) 0.32 <0.001 
Coumestrol 0.08 (0.04, 0.16) 0.09 (0.04, 0.16) 0.08 (0.04, 0.17) 0.46 0.65 
Formononetin 0.01 (0.01, 0.02) 0.01 (0.00, 0.02) 0.01 (0.01, 0.02) 0.38 0.11 
Biochanin A 0.05 (0.03, 0.08) 0.05 (0.04, 0.08) 0.05 (0.03, 0.08) 0.08 0.06 
1 Values are medians (interquartile ranges) 
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Table 8: HRs (95% CIs) for advanced prostate cancer according to quintiles of total and individual 
phytoestrogen intake (mg/day) in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
  Advanced Prostate Cancer Cases 
Phytoestrogens (mg/day) No. of Cases Person Years Crude HR (95% CI) Adjusted HR (95% CI)1 
Total Phytoestrogens         
Q1 (0.0 - 0.29) 57 3,644 Reference Reference 
Q2 (0.30 - 0.50) 78 4,972 1.35 (0.96 - 1.89) 1.27 (0.90 - 1.81) 
Q3 (0.51 - 0.77) 87 5,702 1.47 (1.06 - 2.06)* 1.29 (0.91 - 1.82) 
Q4 (0.78 - 1.22) 85 5,446 1.46 (1.04 - 2.04)* 1.28 (0.90 - 1.81) 
Q5 (1.23 - 68.66) 89 5,783 1.52 (1.09 - 2.11)* 1.41 (0.99 - 2.01) 
p-trend     0.06 0.13 
Isoflavones         
Q1 (0.0 - 0.18) 54 3,452 Reference Reference 
Q2 (0.19 - 0.34) 76 4,798 1.40 (0.99 - 1.99) 1.29 (0.91 - 1.85) 
Q3 (0.35 - 0.54) 89 5,807 1.58 (1.13 - 2.22)* 1.30 (0.92 - 1.84) 
Q4 (0.55 - 0.85) 82 5,295 1.48 (1.05 - 2.09)* 1.25 (0.88 - 1.79) 
Q5 (0.86 - 66.31) 95 6,195 1.72 (1.23 - 2.40)* 1.58 (1.11 - 2.24)* 
p-trend     0.010 0.028 
Genistein         
Q1 (0.0 - 0.04) 59 3,836 Reference Reference 
Q2 (0.05 - 0.11) 72 4,495 1.21 (0.86 - 1.71) 1.19 (0.84 - 1.70) 
Q3 (0.12 - 0.22) 88 5,706 1.43 (1.03 - 1.99)* 1.19 (0.85 - 1.68) 
Q4 (0.23 - 0.39) 95 6,157 1.57 (1.13 - 2.17)* 1.42 (1.02 - 1.98)* 
Q5 (0.40 - 37.07) 82 5,353 1.35 (0.96 - 1.88) 1.25 (0.87 - 1.78) 
p-trend     0.16 0.29 
Daidzein         
Q1 (0.0 - 0.12) 51 3,233 Reference Reference 
Q2 (0.13 - 0.20) 86 5,533 1.67 (1.18 - 2.36)* 1.57 (1.10 - 2.23)* 
Q3 (0.21 - 0.31) 90 5,852 1.71 (1.21 - 2.41)* 1.50 (1.05 - 2.14)* 
Q4 (0.32 - 0.47) 74 4,769 1.43 (1.00 - 2.04) 1.27 (0.88 - 1.83) 
Q5 (0.48 - 27.18) 95 6,160 1.82 (1.29 - 2.56)* 1.62 (1.13 - 2.32)* 
p-trend     0.017 0.11 
Glycitein         
Q1 (0.0 - 0.001) 63 4,028 Reference Reference 
Q2 (0.002 - 0.003) 69 4,349 1.04 (0.74 - 1.47) 1.11 (0.78 - 1.57) 
Q3 (0.004 - 0.010) 87 5,646 1.50 (1.09 - 2.08)* 1.38 (0.99 - 1.93) 
Q4 (0.011 - 0.030) 85 5,632 1.50 (1.08 - 2.07)* 1.28 (0.91 - 1.81) 
Q5 (0.031 - 3.130) 91 5,892 1.51 (1.09 - 2.08)* 1.53 (1.09 - 2.15)* 
p-trend     0.021 0.027 
Coumestrol         
Q1 (0.0 - 0.03) 75 4,894 Reference Reference 
Q2 (0.04 - 0.07) 73 4,690 1.01 (0.73 - 1.39) 1.02 (0.73 - 1.42) 
Q3 (0.08 - 0.11) 86 5,582 1.18 (0.87 - 1.61) 1.13 (0.82 - 1.56) 
Q4 (0.12 - 0.20) 85 5,409 1.16 (0.85 - 1.58) 1.14 (0.83 - 1.57) 
Q5 (0.21 - 2.19) 77 4,972 1.07 (0.78 - 1.46) 1.05 (0.76 - 1.45) 
p-trend     0.80 0.89 
Formononetin         
Q1 (0.0 - 0.006) 77 4,952 Reference Reference 
Q2 (0.007 - 0.010) 93 6,055 1.46 (1.08 - 1.97)* 1.42 (1.04 - 1.93)* 
Q3 (0.011 - 0.014) 69 4,404 1.29 (0.93 - 1.78) 1.26 (0.90 - 1.75) 
Q4 (0.015 - 0.020) 74 4,802 1.26 (0.92 - 1.74) 1.21 (0.87 - 1.67) 
Q5 (0.021 - 0.240) 83 5,334 1.42 (1.04 - 1.93)* 1.30 (0.95 - 1.79) 
p-trend     0.12 0.34 
Biochanin A         
Q1 (0.0 - 0.030) 69 4,498 Reference Reference 
Q2 (0.031 - 0.040) 74 4,771 1.11 (0.80 - 1.55) 1.08 (0.78 - 1.51) 
Q3 (0.041 - 0.060) 83 5,378 1.24 (0.90 - 1.71) 1.16 (0.84 - 1.61) 
Q4 (0.061 - 0.090) 95 6,119 1.44 (1.05 - 1.96)* 1.31 (0.95 - 1.80) 
Q5 (0.091 - 0.590) 75 4,781 1.14 (0.82 - 1.59) 1.03 (0.74 - 1.44) 
p-trend     0.36 0.84 
1Adjusted for age, race/ethnicity, BMI, smoking status, alcohol intake, and family history of prostate cancer 
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Table 9: HRs (95% CIs) for non-advanced prostate cancer according to quintiles of total and individual 
phytoestrogen intake (mg/day) in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
  Non-Advanced Prostate Cancer Cases 
Phytoestrogens (mg/day) No. of Cases Person Years Crude HR (95% CI) Adjusted HR (95% CI)1 
Total Phytoestrogens         
Q1 (0.0 - 0.29) 627 39,110 Reference Reference 
Q2 (0.30 - 0.50) 674 42,683 1.07 (0.96 - 1.19) 1.03 (0.92 - 1.15) 
Q3 (0.51 - 0.77) 674 43,104 1.06 (0.95 - 1.18) 0.98 (0.88 - 1.10) 
Q4 (0.78 - 1.22) 672 42,733 1.06 (0.95 - 1.18) 1.00 (0.89 - 1.12) 
Q5 (1.23 - 68.66) 585 37,191 0.92 (0.82 - 1.03) 0.95 (0.85 - 1.07) 
p-trend     0.022 0.30 
Isoflavones         
Q1 (0.0 - 0.18) 633 39,466 Reference Reference 
Q2 (0.19 - 0.34) 658 41,264 1.04 (0.94 - 1.16) 1.03 (0.92 - 1.15) 
Q3 (0.35 - 0.54) 654 42,377 1.02 (0.92 - 1.14) 0.92 (0.82 - 1.03) 
Q4 (0.55 - 0.85) 697 44,220 1.09 (0.98 - 1.22) 1.03 (0.92 - 1.15) 
Q5 (0.86 - 66.31) 590 37,494 0.92 (0.82 - 1.03) 0.95 (0.85 - 1.07) 
p-trend     0.08 0.50 
Genistein         
Q1 (0.0 - 0.04) 670 42,006 Reference Reference 
Q2 (0.05 - 0.11) 637 39,702 0.95 (0.85 - 1.05) 0.94 (0.84 - 1.04) 
Q3 (0.12 - 0.22) 663 42,935 0.97 (0.87 - 1.08) 0.87 (0.78 - 0.97)* 
Q4 (0.23 - 0.39) 689 43,897 1.02 (0.92 - 1.13) 0.95 (0.85 - 1.06) 
Q5 (0.40 - 37.07) 573 36,281 0.84 (0.75 - 0.94)* 0.88 (0.78 - 0.99)* 
p-trend     0.005 0.14 
Daidzein         
Q1 (0.0 - 0.12) 620 38,682 Reference Reference 
Q2 (0.13 - 0.20) 670 42,386 1.08 (0.97 - 1.21) 1.04 (0.93 - 1.16) 
Q3 (0.21 - 0.31) 662 42,388 1.06 (0.95 - 1.18) 0.98 (0.87 - 1.09) 
Q4 (0.32 - 0.47) 663 42,014 1.07 (0.96 - 1.19) 1.01 (0.90 - 1.13) 
Q5 (0.48 - 27.18) 617 39,351 0.99 (0.88 - 1.10) 1.01 (0.90 - 1.14) 
p-trend     0.39 0.95 
Glycitein         
Q1 (0.0 - 0.001) 667 41,809 Reference Reference 
Q2 (0.002 - 0.003) 702 43,885 1.01 (0.91 - 1.112) 1.04 (0.94 - 1.16) 
Q3 (0.004 - 0.010) 635 40,698 1.06 (0.95 - 1.18) 1.00 (0.89 - 1.12) 
Q4 (0.011 - 0.030) 665 43,068 1.13 (1.02 - 1.26)* 1.03 (0.92 - 1.15) 
Q5 (0.031 - 3.130) 563 35,361 0.89 (0.80 - 1.00)* 0.96 (0.86 - 1.08) 
p-trend     0.012 0.31 
Coumestrol         
Q1 (0.0 - 0.03) 672 42,560 Reference Reference 
Q2 (0.04 - 0.07) 632 39,921 0.98 (0.88 - 1.09) 0.96 (0.86 - 1.07) 
Q3 (0.08 - 0.11) 678 42,725 1.04 (0.94 0 1.16) 1.03 (0.92 - 1.14) 
Q4 (0.12 - 0.20) 631 40,196 0.96 (0.86 - 1.07) 0.94 (0.84 - 1.05) 
Q5 (0.21 - 2.19) 619 39,419 0.95 (0.85 - 1.06) 0.96 (0.86 - 1.07) 
p-trend     0.26 0.41 
Formononetin         
Q1 (0.0 - 0.006) 777 49,098 Reference Reference 
Q2 (0.007 - 0.010) 682 42,934 1.06 (0.96 - 1.18) 1.06 (0.95 - 1.17) 
Q3 (0.011 - 0.014) 553 34,885 1.03 (0.92 - 1.15) 1.01 (0.90 - 1.13) 
Q4 (0.015 - 0.020) 608 38,814 1.03 (0.93 - 1.15) 1.00 (0.89 - 1.11) 
Q5 (0.021 - 0.240) 612 39,090 1.04 (0.93 - 1.15) 1.01 (0.91 - 1.13) 
p-trend     0.69 0.90 
Biochanin A         
Q1 (0.0 - 0.030) 668 42,067 Reference Reference 
Q2 (0.031 - 0.040) 610 38,502 0.95 (0.86 - 1.06) 0.92 (0.82 - 1.03) 
Q3 (0.041 - 0.060) 655 41,467 1.02 (0.92 - 1.14) 0.99 (0.89 - 1.10) 
Q4 (0.061 - 0.090) 638 40,557 1.00 )0.90 - 1.12) 0.94 (0.85 - 1.06) 
Q5 (0.091 - 0.590) 661 42,228 1.04 (0.94 - 1.16) 0.99 (0.89 - 1.11) 
p-trend     0.24 0.78 
1Adjusted for age, race/ethnicity, BMI, smoking status, alcohol intake, and family history of prostate cancer 
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Table 10: HRs (95% CIs) for all prostate cancer according to quintiles of total and individual 
phytoestrogen intake (mg/day) in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
  Total Prostate Cancer Cases 
Phytoestrogens (mg/day) No. of Cases Person Years Crude HR (95% CI) Adjusted HR (95% CI)1 
Total Phytoestrogens         
Q1 (0.0 - 0.29) 684 42,754 Reference Reference 
Q2 (0.30 - 0.50) 752 47,655 1.09 (0.99 - 1.21) 1.05 (0.94 - 1.16) 
Q3 (0.51 - 0.77) 761 48,806 1.10 (0.99 - 1.22) 1.01 (0.90 - 1.12) 
Q4 (0.78 - 1.22) 757 48,179 1.10 (0.99 - 1.21) 1.02 (0.92 - 1.14) 
Q5 (1.23 - 68.66) 674 42,974 0.97 (0.87 - 1.08) 0.99 (0.89 - 1.11) 
p-trend     0.12 0.63 
Isoflavones         
Q1 (0.0 - 0.18) 687 42,918 Reference Reference 
Q2 (0.19 - 0.34) 734 46,062 1.07 (0.97 - 1.19) 1.05 (0.94 - 1.17) 
Q3 (0.35 - 0.54) 743 48,184 1.07 (0.96 - 1.18) 0.95 (0.85 - 1.06) 
Q4 (0.55 - 0.85) 779 49,515 1.12 (1.02 - 1.25) 1.05 (0.94 - 1.17) 
Q5 (0.86 - 66.31) 685 43,689 0.98 (0.89 - 1.09) 1.01 (0.90 - 1.12) 
p-trend     0.43 0.94 
Genistein         
Q1 (0.0 - 0.04) 729 45,842 Reference Reference 
Q2 (0.05 - 0.11) 709 44,197 0.97 (0.87 - 1.07) 0.96 (0.86 - 1.06) 
Q3 (0.12 - 0.22) 751 48,641 1.01 (0.91 - 1.12) 0.90 (0.81 - 1.00)* 
Q4 (0.23 - 0.39) 784 50,054 1.06 (0.96 - 1.18) 0.99 (0.89 - 1.10) 
Q5 (0.40 - 37.07) 655 41,634 0.88 (0.79 - 0.98)* 0.91 (0.81 - 1.02) 
p-trend     0.029 0.29 
Daidzein         
Q1 (0.0 - 0.12) 671 41,915 Reference Reference 
Q2 (0.13 - 0.20) 756 47,919 1.13 (1.02 - 1.25)* 1.08 (0.97 - 1.20) 
Q3 (0.21 - 0.31) 752 48,240 1.11 (1.00 - 1.23) 1.02 (0.91 - 1.13) 
Q4 (0.32 - 0.47) 737 46,783 1.10 (0.99 - 1.22) 1.03 (0.92 - 1.14) 
Q5 (0.48 - 27.18) 712 45,511 1.05 (0.95 - 1.17) 1.06 (0.95 - 1.18) 
p-trend     0.98 0.56 
Glycitein         
Q1 (0.0 - 0.001) 730 45,837 Reference Reference 
Q2 (0.002 - 0.003) 771 48,234 1.01 (0.91 - 1.12) 1.05 (0.95 - 1.16) 
Q3 (0.004 - 0.010) 722 46,344 1.10 (0.99 - 1.22) 1.03 (0.93 - 1.15) 
Q4 (0.011 - 0.030) 750 48,700 1.16 (1.05 - 1.29)* 1.05 (0.95 - 1.17) 
Q5 (0.031 - 3.130) 654 41,253 0.95 (0.85 - 1.05) 1.01 (0.91 - 1.13) 
p-trend     0.11 0.81 
Coumestrol         
Q1 (0.0 - 0.03) 747 47,454 Reference Reference 
Q2 (0.04 - 0.07) 705 44,611 0.98 (0.88 - 1.09) 0.96 (0.87 - 1.07) 
Q3 (0.08 - 0.11) 764 48,307 1.06 (0.96 - 1.17) 1.04 (0.93 - 1.15) 
Q4 (0.12 - 0.20) 716 45,605 0.98 (0.89 - 1.09) 0.96 (0.87 - 1.07) 
Q5 (0.21 - 2.19) 696 44,391 0.96 (0.87 - 1.07) 0.97 (0.87 - 1.07) 
p-trend     0.33 0.47 
Formononetin         
Q1 (0.0 - 0.006) 854 54,050 Reference Reference 
Q2 (0.007 - 0.010) 775 48,989 1.10 (0.99 - 1.21) 1.09 (0.99 - 1.20) 
Q3 (0.011 - 0.014) 622 39,289 1.05 (0.95 - 1.17) 1.03 (0.93 - 1.14) 
Q4 (0.015 - 0.020) 682 43,616 1.05 (0.95 - 1.17) 1.01 (0.91 - 1.12) 
Q5 (0.021 - 0.240) 695 44,424 1.07 (0.97 - 1.18) 1.04 (0.94 - 1.15) 
p-trend     0.37 0.84 
Biochanin A         
Q1 (0.0 - 0.030) 737 46,565 Reference Reference 
Q2 (0.031 - 0.040) 684 43,273 0.97 (0.87 - 1.08) 0.93 (0.84 - 1.04) 
Q3 (0.041 - 0.060) 738 46,845 1.04 (0.94 - 1.16) 1.00 (0.90 - 1.11) 
Q4 (0.061 - 0.090) 733 46,676 1.05 (0.94 - 1.16) 0.98 (0.88 - 1.09) 
Q5 (0.091 - 0.590) 736 47,009 1.05 (0.95 - 1.17) 1.00 (0.90 - 1.10) 
p-trend     0.16 0.74 
1Adjusted for age, race/ethnicity, BMI, smoking status, alcohol intake, and family history of prostate cancer 
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Chapter 4 
 
Association between Urinary Phytoestrogens and C-Reactive Protein in the 
Continuous National Health and Nutrition Examination Survey 
89 
 
Abstract 
Serum C-reactive protein (CRP) is an inflammatory biomarker.  The potential 
protective effect of phytoestrogen intake on cancer risk may be mediated in part through 
its influence on serum CRP levels.  This study is among the first to examine the 
associations between urinary concentrations of total and individual phytoestrogens and 
serum concentrations of CRP among 6,009 subjects aged ≥40 years in the continuous 
National Health and Nutrition Examination Survey (1999-2010).  Phytoestrogen 
concentrations in spot urine (ng/mL) were measured using high performance liquid 
chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection.  Serum 
CRP levels (mg/L) were quantified by latex-enhanced nephelometry.  After adjustment 
for urinary creatinine and other confounders, both linear and logistic regression analyses 
showed a significant inverse association between urinary excretion of total and all 
individual phytoestrogens and serum levels of CRP.  Total phytoestrogens (β: -0.11; 95% 
CI: -0.13, -0.09) were associated with the largest reduction in CRP levels, followed by 
total lignans (β: -0.08; 95% CI: -0.10, -0.06) and enterolactone (β: -0.07; 95% CI: -0.08, -
0.05).  A reduced risk of developing high concentrations of CRP (≥ 3.0 mg/L) was most 
pronounced for enterolactone (OR for quartile 4 vs. quartile 1: 0.59; 95% CI: 0.51, 0.69), 
followed by total phytoestrogens (OR for quartile 4 vs. quartile 1: 0.63; 95% CI: 0.53, 
0.73) and lignans (OR for quartile 4 vs. quartile 1: 0.64; 95% CI: 0.54, 0.75).  In 
summary, dietary intake of total and individual phytoestrogens, assessed by measuring 
their urinary biomarkers, reduced the concentrations of CRP in a large, nationally 
representative sample of the US population.
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Introduction 
C-reactive protein (CRP) is a ring-shaped protein found in the plasma.  It is the 
classical acute phase reactant, with the concentration rising rapidly in a cytokine-
mediated response due to tissue injury, infection, or inflammation.  Serum CRP levels are 
routinely measured to detect and monitor many human diseases (218).  In past studies, 
elevated CRP levels have been associated with both cancer (219, 220) and cardiovascular 
disease (221, 222).  A study using the Women’s Health Initiative population showed that 
CRP levels are elevated before vascular events (223), and other studies have indicated 
that the use of oral estrogen may increase CRP levels as well (224).  Inflammation has 
been linked to carcinogenesis (225) and certain inflammatory diseases have been 
associated with an increased risk of cancer through such mechanisms as the inhibition of 
apoptosis (226), prolonged activation of signal transducer and activator of transcription 3 
(STAT3) (227), and the deactivation of tumor necrosis factor alpha (TNF-α) (228).  In-
vitro and animal studies have indicated that CRP may be an active participant in plaque 
development through such mechanisms as monocyte adhesion to the endothelium (229) 
and macrophage cholesterol accumulation (230). 
Where CRP has been linked to an increase in the risk of chronic conditions, 
phytoestrogens, a group of compounds found in plants with a structural similarity to 
estrogen (12), have been associated with a decreased risk (168, 169).  The biological 
effects seen in epidemiologic and experimental studies due to the consumption of 
phytoestrogens is caused by their competitive binding to estrogen receptors (136, 137).  
There are two principal classes of phytoestrogens, isoflavones and lignans.  The most 
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important dietary source of isoflavones is soy products (43, 125), whereas dietary lignans 
primarily originate in flax seed (69).  Both isoflavones and lignans are metabolized in the 
gut bacteria to form additional compounds that can act on the human body through 
competitive binding (76, 128).   
Intake of total and individual phytoestrogens and their biomarkers have been 
associated with a decreased risk of both cancer and cardiovascular disease (132, 133), 
however the underlying mechanisms for these associations remain unclear.  Studies 
conducted on the effects of phytoestrogens and CRP have shown mixed results, with 
some studies showing certain individual phytoestrogens may reduce CRP levels (115), 
and others showing no effect on CRP (231).  However, many of these studies were 
conducted on specific groups of subjects such as postmenopausal women.  Little is 
known about the association between phytoestrogens and CRP in a larger, more diverse 
sample of subjects.  To date, no epidemiologic studies have evaluated the association 
between phytoestrogen intake and CRP levels in a nationally representative sample of the 
US population.  Therefore, the present study investigated this research question using 
data on urinary excretion of total and individual phytoestrogens and serum CRP 
concentrations, previously collected from the continuous National Health and Nutrition 
Examination Survey (NHANES). 
Subjects and Methods 
Study Population 
Data analyzed in this study were obtained from the NHANES for the years 1999-
2010.  This data source was selected because the collection of urinary phytoestrogen data 
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began in 1999.  NHANES is an annual cross-sectional study initiated in the current form 
in 1999 by the Center for Disease Prevention and Control (CDC) to assess the health and 
nutritional status of the general US population.  Data collection and sampling procedures 
for NHANES have been described in detail elsewhere (151). 
From 1999 to 2010, a total of 62,160 individuals who enrolled in the NHANES also 
completed the interview and health examination components.  As the objective of the 
present study is to investigate the association between urinary phytoestrogens and CRP 
and the relationship to cancer and cardiovascular disease, the analyses were confined to 
subjects who were 40 years of age or older.  Urinary concentrations of phytoestrogens 
and CRP levels were measured only among a subsample of total NHANES participants.  
Subsampling in NHANES was performed to reduce participant burden and facilitate 
scheduling and completion of examinations.  All subjects in the subsamples were 
randomly selected from the pool of total participants to obtain a nationally representative 
sample, with subsample weights calculated to account for the probability of being 
selected into the subsample and additional non-response (152).  Excluding subjects who 
were <40 years of age, or without data on urinary phytoestrogens and CRP, left 6,009 
subjects in the study for analysis.  The de-identified data analyzed in the present study are 
freely available in public domains, and the approval for such data analysis by the 
Institutional Review Board of Indiana University was sought but determined not to be 
applicable. 
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Baseline Data Collection 
NHANES participants were interviewed to collect data on demographic and lifestyle 
variables.  Demographic variables used in this study included age, sex, race (non-
Hispanic white, non-Hispanic black, and other race including multiracial), and education 
level (less than high school, high school graduate or equivalent, and more than high 
school).  Lifestyle variables relevant to this study include smoking status [never smokers 
(smoking 0 to <100 cigarettes in lifetime), former smokers (smoking ≥100 cigarettes in 
lifetime but not currently smoking), and current smoker], alcohol consumption (0 
drink/week, <1 drink/week, and >1 drink/week), and nutrient intake through a 24-hour 
food recall.  Body mass index (BMI defined as kg/m2) was calculated from height and 
weight measured during the medical examination portion of data collection. 
 
Urinary Phytoestrogen Measurement 
Phytoestrogen biomonitoring was accomplished by measuring urinary excretion of 
isoflavones (including daidzein, genistein, equol, and O-desmethylangolensin) and 
lignans (including enterodiol, and enterolactone) using high performance liquid 
chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection (153).  The 
methods for the collection and analysis of urine samples for phytoestrogen concentrations 
have been described in detail elsewhere (154).  Briefly, spot urine specimens were 
collected at the Mobile Examination Centers the morning after a recommended fast, 
processed, stored at -200C, and then shipped to the Division of Environmental Health 
Laboratory Sciences at the NCHS for analysis.  Urine samples were amended with stable 
isotope-labeled internal standards to improve method accuracy and precision, incubated 
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with a deconjugation enzyme to allow the quantification of individual phytoestrogens, 
extracted using solid phase extraction to remove interferences and improve sensitivity, 
and then analyzed using negative ion mode electrospray ionization HPLC-MS/MS, an 
assay with a high degree of specificity for each analyte (154).  Previous studies have 
shown that laboratory measurement of phytoestrogen concentrations in the urine are a 
reliable biomarker of phytoestrogen intake (131, 148). 
 
C-reactive protein 
 The level of CRP was determined by analyzing a blood specimen collected from the 
subjects.  The methods for the collection and analysis of blood samples for CRP have 
been described in detail elsewhere (232).  Briefly, blood samples were collected, 
processed, stored frozen at -20o C or less, and shipped to the University of Washington in 
Seattle for analysis.  CRP was quantified using latex-enhanced nephelometry.  Particle 
enhanced assays were based on the reaction between a soluble analyte and the 
corresponding antigen or antibody bound to polystyrene particles.  Particles consisting of 
a polystyrene core and a hydrophilic shell were used to link anti-CRP antibodies 
covalently.  A diluted solution of each test sample was mixed with latex particles coated 
with mouse monoclonal anti-CRP antibodies.  CRP present in the test sample forms an 
antigen-antibody complex with the latex particles.  CRP concentrations were calculated 
by using a calibration curve.  Data reduction of the signals was performed using a 
storable logit-log function for the calibration curve.  These assays were performed on a 
Behring Nephelometer for quantitative CRP determination (232). 
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Statistical analysis 
Sample weights were applied to the data through the calculation of a twelve-year 
weight variable according to the guidelines from the National Center for Health Statistics 
(NCHS) when combining two or more two-year cycles of the continuous NHANES data, 
to produce an unbiased national estimate.  Total phytoestrogens were calculated by 
summing all of the individual phytoestrogens, with a similar calculation completed for 
both total isoflavones and total lignans.  Demographic, anthropometric, lifestyle 
characteristics of subjects (including age, gender, race, BMI, education, smoking status, 
and alcohol intake) and total and individual phytoestrogen urinary concentrations 
(ng/mL) were compared by the quartiles of CRP level (mg/L) (Q1: 0.1 – 0.8; Q2: 0.9 – 
2.1; Q3: 2.2 – 4.9; Q4: 5.0 – 296.0).  Chi-square tests and analysis of variance were 
employed to compare differences in categorical and continuous variables among 
quartiles, respectively. 
Multiple linear regression analyses were performed to determine the association 
between total and individual phytoestrogens and CRP levels.  Urinary phytoestrogens and 
CRP levels were log-transformed for statistical analyses.  Additionally, binary logistic 
regression analyses were used to calculate odds ratios (ORs) and 95% confidence 
intervals (CIs) for having a CRP of 3.0 mg/L or greater associated with quartiles of 
urinary phytoestrogens.  Previous studies have shown that CRP levels > 3.0 mg/L are 
associated with an increased risk of cancer (233) and cardiovascular disease (234).  For 
the logistic regression analyses, each urinary phytoestrogen was divided into quartiles 
(with the first quartile used as the reference group) to determine the association with 
higher CRP levels (≥ 3.0 mg/L).  The variables adjusted in the multivariable models of 
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both the linear and logistic regressions were age, gender, race, education, BMI, smoking 
status, alcohol intake, and urinary creatinine.  Urinary creatinine was included to adjust 
for the variation in urinary dilution, which is a commonly used method (148, 177).  Three 
separate models were analyzed, Model 1: adjusted for creatinine level; Model 2: further 
adjusted for age, gender, and race; and Model 3: further adjusted for education, BMI, 
smoking status, and alcohol intake.  No interactions were found to be statistically 
significant, and thus no interaction terms were included in the final models.  Factors that 
were tested for their interactions with urinary phytoestrogens in relation to CRP 
concentrations included age, gender, BMI, education, smoking status, total energy intake, 
and sodium intake.  Marital status, and intake of alcohol, total energy, sodium, fat, and 
calcium were examined as potential confounders but not included in the final models 
because they were not statistically significant or did not substantively alter risk estimates 
(<10%).  Two-sided p-values of <0.05 were considered statistically significant.  SPSS 
version 21 was used for all statistical analyses. 
 Results 
Characteristics of study subjects by CRP quartile are shown in Table 11.  Subjects 
were statistically significantly different across CRP quartiles for age, gender, race, 
education, smoking status, and alcohol intake.  Those in the highest quartile of CRP were 
more likely to be female, non-Hispanic black, obese, current smokers and non-drinkers, 
but were less likely to be in the higher education group.  For the comparison of total and 
individual phytoestrogens, those in the highest quartile of CRP had statistically 
significantly decreased urinary concentrations of all phytoestrogens measurements, with 
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the exception of equol and enterodiol, which did not show significant differences 
between the quartiles.   
Table 12 shows the results of the multiple linear regression.  These analyses show 
that an increased level of each of the total and individual phytoestrogens were associated 
with a decrease in CRP levels, as all of the β coefficients in each model are negative and 
statistically significant.  In the full model (Model 3), total phytoestrogens were associated 
with the largest decrease in CRP levels (β: -0.11; 95% CI: -0.13, -0.09), followed by total 
lignans (β: -0.08; 95% CI: -0.10, -0.06) and enterolactone (β: -0.07; 95% CI: -0.08, -
0.05), respectively. 
Table 13 shows the results of the binary multiple logistic regression analyses.  The 
numbers of subjects in each phytoestrogen quartile with CRP levels ≥ 3.0 mg/L and < 3.0 
mg/L are displayed in the table.  The highest number of subjects with CRP levels ≥ 3.0 
mg/L was associated with the first quartile of each phytoestrogen measurement, except 
for genistein and daidzein, which showed the highest number of subjects in the second 
quartile.  Similar to the results from the linear regression, higher urinary concentrations 
of each of the total and individual phytoestrogens appeared to have lower concentrations 
of CRP in all three models.  In the full model, the largest decreased odds of having a CRP 
level ≥ 3.0 mg/L was observed for enterolactone (OR for quartile 4 vs. quartile 1: 0.59; 
95% CI: 0.51, 0.69), followed by total phytoestrogens (OR for quartile 4 vs. quartile 1: 
0.63; 95% CI: 0.53, 0.73) and lignans (OR for quartile 4 vs. quartile 1: 0.64; 95% CI: 
0.54, 0.75).  The decreased odds for having a CRP level ≥ 3.0 mg/L for all urinary 
phytoestrogen measurements ranged from 13% to 41% in the highest quartile of the full 
model.     
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Discussion 
The present study investigated the associations between urinary phytoestrogens and 
CRP levels using data collected from a nationally representative sample of the US 
population.  It was found in both the linear and logistic regression analyses that urinary 
concentrations of total and individual phytoestrogens were significantly and inversely 
associated with CRP levels. 
The results of this study are consistent with the results of several other studies in 
which an increased intake of particular phytoestrogens were also associated with a 
decrease in CRP (115, 235-237).  A randomized, double-blind, placebo-controlled, 
dietary intervention crossover trial conducted by Hall et al. found that isoflavones have 
beneficial effects on CRP concentrations, but did not have the same effects on other 
inflammatory biomarkers that are associated with cardiovascular disease.  The group 
receiving the isoflavones showed reduced CRP concentrations compared to those 
receiving the placebo (OR: 0.43; 95% CI: 0.27, 0.69) (115).  Another randomized, 
double-blinded, crossover study also showed a decrease in CRP levels with higher levels 
of phytoestrogens as well (236).   
Two epidemiological studies reported that an increase in phytoestrogen intake 
through dietary supplementation did not alter CRP levels (231, 238).  These two studies 
that observed no association between phytoestrogen intake and CRP levels were 
conducted on very specific groups of people, with one study conducted on only 
postmenopausal women (231) and the other on a small group that included 
postmenopausal women and hypercholesterolemic men (238), which may explain the 
lack of association that was observed.  The results of the current study should be more 
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generalizable since it included all adults over forty years of age in a nationally 
representative sample of the US.    
There are several possible explanations to the present study’s observed reduction of 
CRP levels associated with high phytoestrogen levels.  Previous studies have shown that 
CRP levels may be reduced in the presence of increased levels of antioxidants (239, 240).  
Phytoestrogens have been shown to have antioxidant properties (241, 242), which may 
act to reduce the levels of circulating CRP.  Additionally, studies have shown that higher 
levels of circulating estrogen due to orally delivered estrogen therapy are associated with 
increased levels of plasma CRP (224, 243, 244).  Phytoestrogens are weak estrogens, 
with a much higher concentration needed to produce an equivalent biologic response 
(36).  It is possible that competitive binding of phytoestrogens to estrogen receptors may 
decrease the effects of natural or pharmacological estrogens on CRP and therefore alter 
the risk of associated diseases. 
 The present study has several advantages.  This was a large study conducted on a 
nationally representative sample of men and women in the US population.  Large 
epidemiologic studies on the association between phytoestrogens and CRP levels in this 
type of national sample are non-existent.  Most studies to this point have been small trials 
on specific groups of people (post-menopausal women), which reduces the 
generalizability of their results.  Additionally, total and individual phytoestrogens as well 
as CRP levels were measured through laboratory methods, which is free of the recall 
errors that are inherent when food frequency data are used to assess phytoestrogen intake.  
Urinary excretion of phytoestrogens also provides a more accurate representation of 
phytoestrogen intake from all sources, compared to a food frequency questionnaire.  
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Another advantage of measuring urinary phytoestrogens is the measurement of each 
individual phytoestrogen as well as their metabolites that are produced by the intestinal 
bacteria but not associated with dietary intake, such as equol and O-desmethylangolensin 
(71).  Accurate representations of individual phytoestrogens are important to determine 
their association with biomarkers such as CRP, as represented in the findings of this 
study that showed a decreased odds of high CRP levels for individual phytoestrogens 
ranging from 13% to 41%.  This is also true for the association with chronic conditions as 
specific phytoestrogens differ in their levels of biological activity (135).   
  Limitations of the present study need to be considered in the interpretation of the 
obtained results.  This study was a cross-sectional design which only allows for the 
capture of information from one point in time.  This may not accurately reflect an 
individuals’ usual urinary output of phytoestrogens due to within-person variation.  
Longer-term urinary output measures of phytoestrogens were not available from 
NHANES due to feasibility limitations of the study.  The use of spot urine to determine 
phytoestrogen concentrations could be seen as a potential limitation of this study due to 
variation in urinary dilution.  To adjust for this variation, each phytoestrogen 
concentration was normalized to urinary creatinine, a commonly used method (148, 177), 
since creatinine is excreted by glomerular filtration at a relatively constant rate (178).  
Additionally, phytoestrogen concentrations in spot urine, particularly for individual 
isoflavones, have been reported to be statistically significantly correlated with their 
concentrations measured in serum (179).  Finally, a rise in CRP levels has been 
associated with infections (245) as well as traumatic injuries (246).  Data on these 
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variables were not available from NHANES and therefore not controlled for in the 
multivariable analyses. 
In summary, the present study suggests that higher urinary concentrations of total and 
individual phytoestrogens were associated with reduced concentrations of CRP, with the 
largest reduction observed in total phytoestrogens, lignans, and enterolactone.  Increased 
CRP levels have been associated with an increased risk of certain chronic conditions, 
such as cancer (219, 220) and cardiovascular disease (229, 230), whereas increased 
phytoestrogen intake has been associated with a decreased risk of these conditions (168, 
169).  It is important and timely to further investigate the associations of CRP levels with 
phytoestrogen intake, its biomarkers, and metabolic polymorphisms as it is possible that 
the association between phytoestrogens and cancer or cardiovascular disease may be 
mediated through the influence of phytoestrogen intake on circulating levels of CRP. 
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Table 11: Baseline characteristics of subjects by quartiles of C-reactive protein (mg/L) in the continuous 
National Health and Nutrition Examination Survey, 1999-2010 
  C-reactive protein (mg/L) 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4  
Characteristics 0.1 - 0.8 0.9 - 2.1 2.2 - 4.9 5.0 - 296.0  
  n = 1,801 n = 1,847 n = 1,777 n = 1,763 p-value 
Age [Mean (SD)] 54.9 (11.9) 57.3 (12.2) 57.7 (12.2) 56.8 (12.0) <0.001 
Gender (%)      
     Male 52.6 52.1 48.7 36.8 <0.001 
     Female 47.4 47.9 51.3 63.2  
Race/Ethnicity (%)      
     Non-Hispanic White 77.8 76.8 75.2 73.5 <0.001 
     Non-Hispanic Black 7.4 8.5 9.0 13.7  
     Other 14.8 14.7 15.8 12.8  
BMI1 [Mean (SD)] 25.5 (4.4) 27.9 (5.1) 29.7 (5.7) 32.4 (7.8) <0.001 
Education (%)      
     Less than High School 15.5 17.8 22.2 23.6 <0.001 
     High School Graduate or Equivalent 25.7 24.6 27.1 26.7  
     More than High School 58.8 57.6 50.7 49.8  
Smoking Status (%)      
     Never Smoker 51.2 50.9 48.5 46.1 <0.001 
     Former Smoker 32.4 32.4 29.7 28.9  
     Current Smoker 16.4 16.8 21.8 25.0  
Alcohol Intake (%)      
     0 drinks/week 28.7 34.9 37.3 41.3 <0.001 
     < 1 drink per week 37.2 35.6 36.1 37.3  
     > 1 drink per week 34.1 29.6 26.6 21.4  
Phytoestrogens (ng/mL) [Mean (SD)]      
     Total Phytoestrogens 2266.3 (6222.8) 1613.0 (3009.8) 1549.6 (3665.9) 1243.2 (4159.3) <0.001 
     Total Isoflavones 908.6 (3436.7) 639.8 (2152.9) 562.4 (2323.5) 487.5 (1601.8) <0.001 
     Genistein 226.5 (965.5) 166.6 (720.0) 134.5 (615.2) 127.3 (407.0) <0.001 
     Daidzein 481.5 (2028.9) 338.5 (1267.9) 295.6 (1335.9) 253.6 (823.5) <0.001 
     Equol 80.0 (717.4) 51.4 (391.5) 54.1 (445.5) 48.9 (407.4) 0.24 
     O-desmethylangolensin 123.8 (694.5) 85.7 (408.1) 80.6 (510.1) 60.6 (463.2) 0.004 
     Total Lignans 1357.7 (4144.9) 973.3 (1912.4) 987.2 (2688.9) 755.7 (2166.3) <0.001 
     Enterodiol 161.0 (602.6) 119.7 (335.9) 174.0 (1087.4) 187.8 (1800.4) 0.27 
     Enterolactone 1196.7 (3864.2) 853.7 (1730.2) 813.3 (1967.2) 568.2 (1057.0) <0.001 
1 Body Mass Index      
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Table 12: Multiple linear regression analysis of serum C-reactive protein in relation to 
urinary excretion of total and individual phytoestrogens in the continuous National Health 
and Nutrition Examination Survey, 1999-2010 
  C-Reactive Protein (mg/L) 
Phytoestrogens (ng/mL) Model 1 Model 2 Model 3 
Total Phytoestrogens    
     β (95% CI) -0.17 (-0.19, -0.15) -0.19 (-0.22, -0.17) -0.11 (-0.13, -0.09) 
     p-value <0.001 <0.001 <0.001 
Isoflavones    
     β (95% CI) -0.07 (-0.09, -0.05) -0.08 (-0.10, -0.06) -0.05 (-0.07, -0.04) 
     p-value <0.001 <0.001 <0.001 
Genistein    
     β (95% CI) -0.05 (-0.07, -0.03) -0.06 (-0.07, -0.04) -0.04 (-0.05, -0.02) 
     p-value <0.001 <0.001 <0.001 
Daidzein    
     β (95% CI) -0.05 (-0.07, -0.04) -0.06 (-0.08, -0.04) -0.04 (-0.06, -0.03) 
     p-value <0.001 <0.001 <0.001 
Equol    
     β (95% CI) -0.04 (-0.07, -0.02) -0.06 (-0.08, -0.03) -0.03 (-0.05, -0.01) 
     p-value <0.001 <0.001 0.003 
O-desmethylangolensin    
     β (95% CI) -0.05 (-0.06, -0.04) -0.06 (-0.07, -0.05) -0.04 (-0.05, -0.03) 
     p-value <0.001 <0.001 <0.001 
Lignans    
     β (95% CI) -0.13 (-0.15, -0.11) -0.14 (-0.16, -0.13) -0.08 (-0.10, -0.06) 
     p-value <0.001 <0.001 <0.001 
Enterodiol    
     β (95% CI) -0.07 (-0.08, -0.05) -0.08 (-0.10, -0.06) -0.04 (-0.05, -0.02) 
     p-value <0.001 <0.001 <0.001 
Enterolactone    
     β (95% CI) -0.11 (-0.12, -0.09) -0.12 (-0.13, 0.10) -0.07 (-0.08, -0.05) 
     p-value <0.001 <0.001 <0.001 
Model 1: Adjusted for creatinine level 
Model 2: Further adjusted for age, gender, and race 
Model 3: Further adjusted for education, BMI, smoking status, and alcohol intake 
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Table 13: ORs (95% CIs) for high concentrations of C-reactive protein (CRP) (>3mg/L) in relation to 
quartiles of urinary concentrations of total and individual phytoestrogens (ng/mL) in the continuous 
National Health and Nutrition Examination Survey, 1999-2010 
  Quartile of Urinary Phytoestrogens  
Phytoestrogens (ng/mL) Q1 Q2 Q3 Q4 p-trend 
Total Phytoestrogens       
Subjects with CRP ≥ and < 3mg/L 780 / 1017 744 / 1055 633 / 1163 542 / 1254   
Model 1 Reference 0.88 (0.77 - 1.00) 0.66 (0.57 - 0.75) 0.50 (0.43 - 0.58) <0.001 
Model 2 Reference 0.83 (0.72 - 0.95) 0.60 (0.52 - 0.70) 0.45 (0.39 - 0.53) <0.001 
Model 3 Reference 0.88 (0.76 - 1.02) 0.67 (0.58 - 0.78) 0.63 (0.53 - 0.73) <0.001 
Isoflavones       
Subjects with CRP ≥ and < 3mg/L 718 / 1078 696 / 1104 671 / 1124 614 / 1183   
Model 1 Reference 0.90 (078 - 1.03) 0.83 (0.73 - 0.96) 0.72 (0.62 - 0.83) <0.001 
Model 2 Reference 0.89 (0.77 - 1.02) 0.81 (0.71 - 0.94) 0.69 (0.60 - 0.79) <0.001 
Model 3 Reference 0.86 (0.74 - 1.00) 0.75 (0.65 - 0.88) 0.73 (0.63 - 0.86) 0.002 
Genistein       
Subjects with CRP ≥ and < 3mg/L 695 / 1106 701 / 1093 673 / 1124 629 / 1167   
Model 1 Reference 0.98 (0.85 - 1.12) 0.90 (0.78 - 1.03) 0.80 (0.70 - 0.92) 0.001 
Model 2 Reference 0.96 (0.84 - 1.11) 0.89 (0.78 - 1.03) 0.78 (0.67 - 0.90) <0.001 
Model 3 Reference 0.95 (0.82 - 1.11) 0.85 (0.73 - 0.99) 0.80 (0.69 - 0.94) 0.010 
Daidzein       
Subjects with CRP ≥ and < 3mg/L 707 / 1094 710 / 1084 641 / 1156 641 / 1156   
Model 1 Reference 0.97 (0.85 - 1.11) 0.81 (0.71 - 0.93) 0.80 (0.70 - 0.92) 0.003 
Model 2 Reference 0.95 (0.83 - 1.09) 0.80 (0.70 - 0.92) 0.77 (0.67 - 0.89) 0.001 
Model 3 Reference 0.94 (0.81 - 1.09) 0.77 (0.66 - 0.90) 0.79 (0.67 - 0.92) 0.009 
Equol       
Subjects with CRP ≥ and < 3mg/L 682 / 1077 667 / 1087 664 / 1094 616 / 1138   
Model 1 Reference 0.95 (0.83 - 1.09) 0.90 (0.78 - 1.03) 0.78 (0.67 - 0.90) <0.001 
Model 2 Reference 0.94 (0.82 - 1.07) 0.90 (0.78 - 1.03) 0.77 (0.66 - 0.89) <0.001 
Model 3 Reference 0.92 (0.80 - 1.07) 0.91 (0.78 - 1.06) 0.76 (0.65 - 0.89) 0.001 
O-desmethylangolensin       
Subjects with CRP ≥ and < 3mg/L 743 / 1064 697 / 1041 604 / 1154 599 / 1168   
Model 1 Reference 0.93 (0.82 - 1.07) 0.73 (0.63 - 0.83) 0.71 (0.62 - 0.81) <0.001 
Model 2 Reference 0.93 (0.81 - 1.07) 0.71 (0.62 - 0.82) 0.67 (0.58 - 0.77) <0.001 
Model 3 Reference 0.91 (0.78 - 1.05) 0.71 (0.61 - 0.82) 0.72 (0.62 - 0.84) 0.002 
Lignans       
Subjects with CRP ≥ and < 3mg/L 789 / 1008 727 / 1073 639 / 1157 544 / 1251   
Model 1 Reference 0.85 (0.74 - 0.97) 0.68 (0.59 - 0.77) 0.50 (0.44 - 0.58) <0.001 
Model 2 Reference 0.80 (0.70 - 0.92) 0.63 (0.55 - 0.72) 0.46 (0.40 - 0.53) <0.001 
Model 3 Reference 0.87 (0.75 - 1.00) 0.73 (0.63 - 0.85) 0.64 (0.54 - 0.75) <0.001 
Enterodiol       
Subjects with CRP ≥ and < 3mg/L 738 / 1058 649 / 1147 659 / 1137 649 / 1144   
Model 1 Reference 0.79 (0.69 - 0.91) 0.78 (0.68 - 0.90) 0.75 (0.65 - 0.86) 0.004 
Model 2 Reference 0.77 (0.67 - 0.88) 0.76 (0.66 - 0.87) 0.69 (0.60 - 0.79) <0.001 
Model 3 Reference 0.87 (0.75 - 1.01) 0.81 (0.70 - 0.95) 0.87 (0.75 - 1.02) 0.37 
Enterolactone       
Subjects with CRP ≥ and < 3mg/L 805 / 1004 720 / 1075 651 / 1141 522 / 1269   
Model 1 Reference 0.83 (0.73 - 0.95) 0.69 (0.61 - 0.79) 0.48 (0.41 - 0.55) <0.001 
Model 2 Reference 0.80 (0.70 - 0.92) 0.66 (0.58 - 0.76) 0.45 (0.39 - 0.51) <0.001 
Model 3 Reference 0.83 (0.72 - 0.96) 0.76 (0.65 - 0.88) 0.59 (0.51 - 0.69) <0.001 
Model 1: Adjusted for creatinine level 
Model 2: Further adjusted for age, gender, and race 
Model 3: Further adjusted for education, BMI, smoking status, and alcohol intake 
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Chapter 5 
General Discussion, Conclusions, and Perspectives 
The results of the analyses of these three studies provided evidence that the intake of 
both total and individual phytoestrogens alters the risk of cancer and cardiovascular 
disease.  The results of the first study using the NHANES data suggested that increased 
urinary concentration of total lignans were associated with a reduced risk of 
cardiovascular disease mortality.  In addition, increased concentrations of both total 
lignans and enterolactone were associated with a reduced risk of all-cause mortality.  
Conversely, increased concentrations of total isoflavones and daidzein were associated 
with an increased risk of both cardiovascular and all-cause mortality.  The results of the 
second study using the PLCO data suggested that higher dietary intake of isoflavones, 
genistein, daidzein, and glycitein were associated with an increased risk of development 
of advanced prostate cancer.  Conversely, higher dietary intake of genistein was 
associated with a reduced risk of non-advanced, and total prostate cancer.  Finally, the 
results of the third study using the NHANES data suggested that higher urinary 
concentrations of total and individual phytoestrogens were associated with reduced 
concentrations of CRP, with the largest reduction observed in total phytoestrogens, 
lignans, and enterolactone.  Increased CRP levels have been associated with an increased 
risk of certain chronic conditions, such as cardiovascular disease (229, 230), whereas 
increased phytoestrogen intake has been associated with a decreased risk of these 
conditions (168, 169).   
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The results of these studies added to the knowledge of modifiable risk factors that 
may either increase or decrease the risk of prostate cancer or cardiovascular disease.  The 
identification of modifiable risk factors is important for these types of chronic conditions 
that affect such a large population in the US and the world.  Two results in particular 
from this study have the potential to impact these diseases.  The first of these most 
significant results was that total lignans was significantly associated with a decreased risk 
of cardiovascular disease mortality.  This finding represents a modifiable risk factor that 
may be protective against the condition responsible for the highest number of deaths in 
the US (1).  Although other phytoestrogens (isoflavones and daidzein) were associated 
with an increased risk of cardiovascular disease mortality, these types of phytoestrogens 
are found in the highest concentrations in different foods (43) compared to lignans (126).  
The second most significant result was that the intake of isoflavones, genistein, daidzein, 
and glycitein were associated with an increased risk of the development of advanced 
prostate cancer.  If these results are confirmed in additional studies, the identification of 
these phytoestrogens as a factor that increases the risk of advanced prostate cancer may 
be the most valuable contribution of these studies. 
There are several strengths of these studies that added to the validity of the findings.  
The datasets that were used in the analyses of all of the studies were relatively large and 
in the case of the NHANES data, nationally representative of the US population.  The 
PLCO data was large enough that the cases of prostate cancer could be divided into either 
non-advanced or advanced cases, which allowed for unique analyses of the data that has 
not been attempted on a US population in the past.  Many similar studies conducted in the 
past consisted of small case-control or cross-sectional designs.  The subjects who 
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participated in both the NHANES and the PLCO were followed prospectively, allowing 
for a temporal element to the data analyses.  The prospective nature of the data also 
largely excluded the possibility of reverse causality between phytoestrogens and the 
outcomes of interest. 
Results from these current studies showed both similarities and differences to 
previous published literature.  Although experimental or epidemiologic data are scarce on 
the association between phytoestrogens and cardiovascular disease, there have been a 
small number of studies that show certain phytoestrogens may be associated with a 
decreased risk of cardiovascular disease (167-169).  Although other studies have shown a 
null association between phytoestrogens and cardiovascular disease (170-172), these 
dissimilar results may be because most previous studies have focused on small, specific 
populations such as postmenopausal women, or the differences in the outcome measures 
between previous studies and this first study.   
Many previous studies have suggested that dietary intake of genistein or other 
isoflavones may exert different effects on specific types of cancer (159, 160, 163), 
however the current first study showed no association with cancer mortality for any of the 
phytoestrogen measurements.  Although the risk of certain cancers may be altered by the 
intake of phytoestrogens, this cannot be assumed for all variations of this disease.  Given 
the small number of total cancer deaths (n=79) in the first study, it was not possible to 
examine cancer-specific associations with total and individual phytoestrogens, which 
may account for the differences that observed in previous studies.   
The results of the second study showed both a significant increased risk between of 
advanced prostate cancer, and a significant decreased risk of non-advanced and total 
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prostate cancer associated with dietary genistein.  Most previous studies have suggested 
that dietary intake of genistein is inversely associated with prostate cancer (159, 182); 
however, one experimental study also suggested that genistein may promote tumor 
progression in advanced prostate cancer (84).  Although it remains unclear why genistein 
simultaneously increased the risk of advanced prostate cancer and decreased the risk of 
non-advanced prostate cancer due to a lack of previous experimental and epidemiologic 
studies, there may be a biologic plausibility for the increased risk of advanced prostate 
cancer observed in the second study.  It has been hypothesized that estrogen may play a 
role in prostate carcinogenesis due to the possible mutagenic effects of estrogen 
metabolites (205).  Phytoestrogens can induce estrogenic responses in the body due to 
their structural similarity to 17β-estradiol (12).  Additionally, increased risk of advanced 
prostate cancer has been observed in patients treated with finasteride, which inhibits the 
conversion of testosterone to dihydrotestosterone, causing an increase of estrogen levels 
(206).  According to the results of these previous studies, it is reasonable to assume that 
an increased intake of phytoestrogens exhibiting increased estrogenic activity would also 
be associated with an increased risk of advanced prostate cancer. 
The results of this third study showed through both linear and logistic regression that 
urinary concentrations of phytoestrogens were significantly inversely associated with 
CRP levels.  These results were consistent with several previous studies that showed 
increased intake of dietary phytoestrogens were associated with a decrease in CRP levels 
(235-237).  However, other studies observed that phytoestrogens did not alter CRP levels 
(231, 238).  Previous studies have shown that CRP levels may be reduced in the presence 
of antioxidants (239, 240) and phytoestrogens have been shown to have antioxidant 
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properties (241, 242).  Additional studies have shown that higher levels of circulating 
estrogens are associated with increased levels of CRP (243, 244).  It is possible that CRP 
levels in the third study were reduced either due to the antioxidant properties of 
phytoestrogens, or the competitive binding of phytoestrogens to estrogen receptors, 
resulting in reduced effects of natural, more biologically potent estrogens on CRP. 
In summary, dietary intake of certain phytoestrogens were found to significantly 
modulate prostate cancer risk and cardiovascular disease mortality.  It is important to 
determine modifiable risk factors that may affect the risk of chronic conditions and 
therefore increase opportunities for primary prevention.  The observed increased risk 
between total and individual isoflavones and advanced prostate cancer may offer an 
innovative, practical avenue for the prevention of biologically relevant manifestations of 
this disease by decreasing the intake of soy products, legumes, and chickpeas.  In 
addition, it is possible that the associations between phytoestrogens and cardiovascular 
disease may be in part mediated through the influence of phytoestrogen intake on 
circulating levels of C-reactive protein.  Since phytoestrogens are biologically weaker 
compared with natural or pharmacological estrogens, an increase in the dietary intake of 
foods containing these compounds may decrease the risk of cardiovascular disease 
through competitive binding to estrogen receptors. 
Further research is needed to confirm the results that were found in these studies.  The 
nature of the data in the first study did not allow for the performance of stratified analyses 
by individual types of cancer or cardiovascular disease.  Updated NHANES data with a 
longer follow-up period may be able to provide new insights into the associations 
between phytoestrogens and specific variations of these chronic conditions.  In the 
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second study, phytoestrogen levels in the PLCO data were estimated using a food 
frequency questionnaire.  Nutritional data collected in this manner is subject to recall bias 
and the levels of certain phytoestrogens may be inadequately represented in food 
composition databases.  Additionally, this method of phytoestrogen measurement is not 
able to quantify phytoestrogen metabolites that are produced in the intestinal bacteria, 
such as equol and O-desmethylangolensin (71).  Future research that is able to investigate 
the effects of total and individual phytoestrogens measured through urinary biomarkers 
on both advanced and non-advanced prostate cancer could help to solidify the findings.  
The use of urinary biomarkers could also quantify the risk between lignans and prostate 
cancer.  In the first study, lignans showed a protective effect associated with 
cardiovascular disease mortality, whereas isoflavones and genistein were associated with 
an increased risk.  The second study showed a similar increased risk between total and 
individual isoflavones and advanced prostate cancer, but data on lignans were not 
available.  It would be interesting to observe the associations between lignans and 
advanced prostate cancer, as lignans and isoflavones originate from different food 
sources.  Finally, the design of the third study was cross-sectional in nature, which only 
allows for the capture of information at one point in time.  These results may not 
accurately reflect the usual intake of phytoestrogens or usual plasma CRP levels.  A 
future study that consists of repeated measures or a longitudinal design could add 
valuable information to the relationship between phytoestrogens and CRP. 
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